PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	collagen, type II, alpha 1	Mus musculus	48-53
33482317-10	2021	The additional utilization of Eudragit EPO for SNEDDS preparations of both complexes successfully maintained the high concentrations of rebamipide in the gastric luminal condition.	rebamipide	136-146	erythropoietin	Homo sapiens	39-42
32589351-10	2021	Additionally, REB administration strongly inhibited the inflammatory response by downregulating both NF-kappaB-p65 and TLR-4.	rebamipide	14-17	toll-like receptor 4	Rattus norvegicus	119-124
33218942-7	2021	The expressions of Tollip, ZO-1 and Claudin-1 in the diclofenac group were down-regulated compared with that in the control group, while they increased significantly in the rebamipide pretreatment group (p < 0.01).	rebamipide	173-183	toll interacting protein	Homo sapiens	19-25
33218942-8	2021	The expressions of TLR4/NF-kappaBp65, IL-1beta, IL-6, IL-8, and TNF-alpha significantly increased in the model group while they were down-regulated in the rebamipide pretreatment group (p < 0.05).	rebamipide	155-165	toll like receptor 4	Homo sapiens	19-23
33218942-8	2021	The expressions of TLR4/NF-kappaBp65, IL-1beta, IL-6, IL-8, and TNF-alpha significantly increased in the model group while they were down-regulated in the rebamipide pretreatment group (p < 0.05).	rebamipide	155-165	interleukin 1 alpha	Homo sapiens	38-46
33218942-8	2021	The expressions of TLR4/NF-kappaBp65, IL-1beta, IL-6, IL-8, and TNF-alpha significantly increased in the model group while they were down-regulated in the rebamipide pretreatment group (p < 0.05).	rebamipide	155-165	interleukin 6	Homo sapiens	48-52
33218942-8	2021	The expressions of TLR4/NF-kappaBp65, IL-1beta, IL-6, IL-8, and TNF-alpha significantly increased in the model group while they were down-regulated in the rebamipide pretreatment group (p < 0.05).	rebamipide	155-165	C-X-C motif chemokine ligand 8	Homo sapiens	54-58
33218942-8	2021	The expressions of TLR4/NF-kappaBp65, IL-1beta, IL-6, IL-8, and TNF-alpha significantly increased in the model group while they were down-regulated in the rebamipide pretreatment group (p < 0.05).	rebamipide	155-165	tumor necrosis factor	Homo sapiens	64-73
33218942-13	2021	CONCLUSION: Rebamipide effectively alleviated intestinal mucosa injury by probably suppressing the TLR4/NF-kappaB signaling pathway and the decreasing of ZO-1 and Claudin-1 induced by diclofenac.	rebamipide	12-22	toll like receptor 4	Homo sapiens	99-103
33218942-13	2021	CONCLUSION: Rebamipide effectively alleviated intestinal mucosa injury by probably suppressing the TLR4/NF-kappaB signaling pathway and the decreasing of ZO-1 and Claudin-1 induced by diclofenac.	rebamipide	12-22	nuclear factor kappa B subunit 1	Homo sapiens	104-113
33218942-13	2021	CONCLUSION: Rebamipide effectively alleviated intestinal mucosa injury by probably suppressing the TLR4/NF-kappaB signaling pathway and the decreasing of ZO-1 and Claudin-1 induced by diclofenac.	rebamipide	12-22	tight junction protein 1	Homo sapiens	154-158
33218942-13	2021	CONCLUSION: Rebamipide effectively alleviated intestinal mucosa injury by probably suppressing the TLR4/NF-kappaB signaling pathway and the decreasing of ZO-1 and Claudin-1 induced by diclofenac.	rebamipide	12-22	claudin 1	Homo sapiens	163-172
33938359-9	2021	Thus, this RSN system developed with distilled water and meglumine is recommended as an oral water-soluble rebamipide-loaded pharmaceutical product.	rebamipide	107-117	CAP-GLY domain containing linker protein 1	Rattus norvegicus	11-14
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	tissue inhibitor of metalloproteinase 3	Mus musculus	55-60
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	transforming growth factor, beta 1	Mus musculus	62-69
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	fibroblast growth factor 2	Mus musculus	75-79
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	interleukin 1 beta	Mus musculus	115-123
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	tumor necrosis factor	Mus musculus	125-133
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	matrix metallopeptidase 3	Mus musculus	146-150
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	matrix metallopeptidase 13	Mus musculus	152-157
31339809-9	2020	Rebamipide up-regulated the mRNA expressions of COL2A, TIMP3, TGFbeta, and FGF2 in chondrocytes and down-regulated IL-1beta, TNFalpha, NF-kappaB, MMP3, MMP13, and ADAMTS5.	rebamipide	0-10	a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 5 (aggrecanase-2)	Mus musculus	163-170
31829321-0	2020	Rebamipide-loaded chitosan nanoparticles accelerate prostatic wound healing by inhibiting M1 macrophage-mediated inflammation via the NF-kappaB signaling pathway.	rebamipide	0-10	nuclear factor kappa B subunit 1	Homo sapiens	134-143
32598706-2	2020	The therapeutic effect of rebamipide based on the induction of cyclooxygenase-2 and increasing level of prostaglandins, inhibition of oxygen free radicals production, epidermal growth factor stimulation, vascular endothelial growth factor, nitric oxide, and decreasing of lipid peroxidation and neutrophils migration.	rebamipide	26-36	prostaglandin-endoperoxide synthase 2	Homo sapiens	63-79
30610666-0	2019	Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with alpha-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson"s Model in Rats.	rebamipide	0-10	synuclein alpha	Rattus norvegicus	82-97
31421154-5	2019	Our results show that the oral administration of rebamipide suppressed SS progression and the level of inflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor-alpha, and IL-17, in the salivary glands and spleen of NOD/ShiLtJ mice.	rebamipide	49-59	interleukin 6	Mus musculus	137-155
31421154-5	2019	Our results show that the oral administration of rebamipide suppressed SS progression and the level of inflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor-alpha, and IL-17, in the salivary glands and spleen of NOD/ShiLtJ mice.	rebamipide	49-59	tumor necrosis factor	Mus musculus	157-184
31421154-5	2019	Our results show that the oral administration of rebamipide suppressed SS progression and the level of inflammatory cytokines, including interleukin (IL)-6, tumor necrosis factor-alpha, and IL-17, in the salivary glands and spleen of NOD/ShiLtJ mice.	rebamipide	49-59	interleukin 17A	Mus musculus	190-195
31421154-6	2019	Rebamipide treatment also increased the number of ex vivo CD19+CD25+Foxp3+ regulatory B cells and CD19+CD5+CD1d + IL-10+ cells in NOD/ShiLtJ mice.	rebamipide	0-10	CD19 antigen	Mus musculus	58-62
31421154-6	2019	Rebamipide treatment also increased the number of ex vivo CD19+CD25+Foxp3+ regulatory B cells and CD19+CD5+CD1d + IL-10+ cells in NOD/ShiLtJ mice.	rebamipide	0-10	interleukin 2 receptor, alpha chain	Mus musculus	63-67
31421154-6	2019	Rebamipide treatment also increased the number of ex vivo CD19+CD25+Foxp3+ regulatory B cells and CD19+CD5+CD1d + IL-10+ cells in NOD/ShiLtJ mice.	rebamipide	0-10	forkhead box P3	Mus musculus	68-73
31421154-6	2019	Rebamipide treatment also increased the number of ex vivo CD19+CD25+Foxp3+ regulatory B cells and CD19+CD5+CD1d + IL-10+ cells in NOD/ShiLtJ mice.	rebamipide	0-10	CD19 antigen	Mus musculus	98-102
31421154-6	2019	Rebamipide treatment also increased the number of ex vivo CD19+CD25+Foxp3+ regulatory B cells and CD19+CD5+CD1d + IL-10+ cells in NOD/ShiLtJ mice.	rebamipide	0-10	CD5 antigen	Mus musculus	103-106
31421154-6	2019	Rebamipide treatment also increased the number of ex vivo CD19+CD25+Foxp3+ regulatory B cells and CD19+CD5+CD1d + IL-10+ cells in NOD/ShiLtJ mice.	rebamipide	0-10	CD1d1 antigen	Mus musculus	107-111
31421154-6	2019	Rebamipide treatment also increased the number of ex vivo CD19+CD25+Foxp3+ regulatory B cells and CD19+CD5+CD1d + IL-10+ cells in NOD/ShiLtJ mice.	rebamipide	0-10	interleukin 10	Mus musculus	114-119
31421154-7	2019	In vitro, rebamipide suppressed IL-6 and IL-17 production by Th17 cells in splenic CD4+ cells from the mice.	rebamipide	10-20	interleukin 6	Mus musculus	32-36
31421154-7	2019	In vitro, rebamipide suppressed IL-6 and IL-17 production by Th17 cells in splenic CD4+ cells from the mice.	rebamipide	10-20	interleukin 17A	Mus musculus	41-46
31421154-7	2019	In vitro, rebamipide suppressed IL-6 and IL-17 production by Th17 cells in splenic CD4+ cells from the mice.	rebamipide	10-20	CD4 antigen	Mus musculus	83-86
30610666-12	2019	Therefore, the anti-PD effect of rebamipide may involve stabilization of mitochondrial bioenergetics, enhancement of GCase enzymatic activity as well as decreased oxidative stress with alpha-synuclein pathology, and apoptosis in 6-OHDA-induced hemiparkinson"s rat model.	rebamipide	33-43	glucosylceramidase beta	Rattus norvegicus	117-122
30610666-12	2019	Therefore, the anti-PD effect of rebamipide may involve stabilization of mitochondrial bioenergetics, enhancement of GCase enzymatic activity as well as decreased oxidative stress with alpha-synuclein pathology, and apoptosis in 6-OHDA-induced hemiparkinson"s rat model.	rebamipide	33-43	synuclein alpha	Rattus norvegicus	185-200
32015381-5	2020	The results of the in vitro examination revealed a significant decrease in TER in the group treated with IL-6 alone compared with the placebo-vehicle group (p < 0.05) and the group treated with IL-6 and rebamipide (p < 0.01).	rebamipide	203-213	interleukin 6	Homo sapiens	105-109
29046162-5	2018	METHODS: Treatment with rebamipide was also found to activate, mitogen-activated protein kinases such as p38, ERK, and JNK to reduce osteoclast differentiation.	rebamipide	24-34	mitogen-activated protein kinase 14	Homo sapiens	105-108
30365413-0	2019	The Effect of Rebamipide Ophthalmic Solution on Cytokine and Mucin Secretion in Culture of Conjunctival Epithelial Cells From the Cu, Zn-Superoxide Dismutase-1 (SOD-1) Knock-Down Mouse.	rebamipide	14-24	superoxide dismutase 1, soluble	Mus musculus	161-166
30365413-1	2019	OBJECTIVES: To evaluate the in vitro effects of 1-mM rebamipide ophthalmic solution on the expression of inflammatory cytokines and MUC5AC in Cu, Zn-superoxide dismutase-1 (SOD-1) knock-down conjunctival epithelium.	rebamipide	53-63	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	132-138
30365413-1	2019	OBJECTIVES: To evaluate the in vitro effects of 1-mM rebamipide ophthalmic solution on the expression of inflammatory cytokines and MUC5AC in Cu, Zn-superoxide dismutase-1 (SOD-1) knock-down conjunctival epithelium.	rebamipide	53-63	superoxide dismutase 1, soluble	Mus musculus	146-171
30365413-1	2019	OBJECTIVES: To evaluate the in vitro effects of 1-mM rebamipide ophthalmic solution on the expression of inflammatory cytokines and MUC5AC in Cu, Zn-superoxide dismutase-1 (SOD-1) knock-down conjunctival epithelium.	rebamipide	53-63	superoxide dismutase 1, soluble	Mus musculus	173-178
30365413-6	2019	RESULTS: After rebamipide ophthalmic solution was applied, IL-6 concentration in the supernatants of conjunctival epithelial cells treated with and without siRNA showed a significant timewise decrease from 0 to 24 hr (963+-42 to 0.07+-0.05 pg/mL and 932+-168 to 2.2+-0.05 pg/mL, respectively) (P&lt;0.001).	rebamipide	15-25	interleukin 6	Mus musculus	59-63
30365413-7	2019	Compared with baseline values, MUC5AC concentrations significantly increased 24 hr after rebamipide application to the conjunctival cultures-both with and without SOD-1 siRNA treatment (P&lt;0.05 in both cases).	rebamipide	89-99	mucin 5, subtypes A and C, tracheobronchial/gastric	Mus musculus	31-37
29251403-0	2018	Rebamipide suppresses TNF-alpha production and macrophage infiltration in the conjunctiva.	rebamipide	0-10	tumor necrosis factor	Mus musculus	22-31
29251403-9	2018	However, conjunctival TNF-alpha level was significantly lower in the rebamipide-treated group compared with the PBS-treated group.	rebamipide	69-79	tumor necrosis factor	Mus musculus	22-31
29251403-11	2018	In addition, TNF-alpha secretion from cultured macrophages was suppressed by rebamipide in a concentration-dependent manner.	rebamipide	77-87	tumor necrosis factor	Mus musculus	13-22
29046162-5	2018	METHODS: Treatment with rebamipide was also found to activate, mitogen-activated protein kinases such as p38, ERK, and JNK to reduce osteoclast differentiation.	rebamipide	24-34	mitogen-activated protein kinase 1	Homo sapiens	110-113
29046162-5	2018	METHODS: Treatment with rebamipide was also found to activate, mitogen-activated protein kinases such as p38, ERK, and JNK to reduce osteoclast differentiation.	rebamipide	24-34	mitogen-activated protein kinase 8	Homo sapiens	119-122
29054700-0	2018	Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins.	rebamipide	0-10	AKT serine/threonine kinase 1	Homo sapiens	78-81
29047150-9	2018	Furthermore, rebamipide significantly increased mucin 2 expression in both the irradiated mouse colon and human colonic epithelial cells.	rebamipide	13-23	mucin 2	Mus musculus	48-55
29625494-0	2018	The Role of 2% Rebamipide Eye Drops Related to Conjunctival Differentiation in Superoxide Dismutase-1 (Sod1) Knockout Mice.	rebamipide	15-25	superoxide dismutase 1, soluble	Mus musculus	79-101
29625494-0	2018	The Role of 2% Rebamipide Eye Drops Related to Conjunctival Differentiation in Superoxide Dismutase-1 (Sod1) Knockout Mice.	rebamipide	15-25	superoxide dismutase 1, soluble	Mus musculus	103-107
29625494-9	2018	Treatment with 2% rebamipide eye drops significantly decreased the corneal fluorescein (P = 0.0093) and Rose Bengal (P = 0.002) staining scores in the Sod1-/- mice.	rebamipide	18-28	superoxide dismutase 1, soluble	Mus musculus	151-155
29625494-11	2018	Conclusions: Topical use of 2% rebamipide drops was observed to improve conjunctival epithelial differentiation and suppress keratinization in the Sod1-/- mice.	rebamipide	31-41	superoxide dismutase 1, soluble	Mus musculus	147-151
29054700-0	2018	Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins.	rebamipide	0-10	mechanistic target of rapamycin kinase	Homo sapiens	82-86
29054700-0	2018	Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins.	rebamipide	0-10	BCL2 apoptosis regulator	Homo sapiens	127-132
29054700-7	2018	In addition, rebamipide increased the levels of phosphorylated Akt and mTOR, enhanced the Bcl-2 and Bcl-xL expressions, and suppressed the expression of Bax and Bim.	rebamipide	13-23	AKT serine/threonine kinase 1	Homo sapiens	63-66
29054700-7	2018	In addition, rebamipide increased the levels of phosphorylated Akt and mTOR, enhanced the Bcl-2 and Bcl-xL expressions, and suppressed the expression of Bax and Bim.	rebamipide	13-23	mechanistic target of rapamycin kinase	Homo sapiens	71-75
29054700-7	2018	In addition, rebamipide increased the levels of phosphorylated Akt and mTOR, enhanced the Bcl-2 and Bcl-xL expressions, and suppressed the expression of Bax and Bim.	rebamipide	13-23	BCL2 apoptosis regulator	Homo sapiens	90-95
29054700-7	2018	In addition, rebamipide increased the levels of phosphorylated Akt and mTOR, enhanced the Bcl-2 and Bcl-xL expressions, and suppressed the expression of Bax and Bim.	rebamipide	13-23	BCL2 like 1	Homo sapiens	100-106
29054700-7	2018	In addition, rebamipide increased the levels of phosphorylated Akt and mTOR, enhanced the Bcl-2 and Bcl-xL expressions, and suppressed the expression of Bax and Bim.	rebamipide	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	153-156
29054700-7	2018	In addition, rebamipide increased the levels of phosphorylated Akt and mTOR, enhanced the Bcl-2 and Bcl-xL expressions, and suppressed the expression of Bax and Bim.	rebamipide	13-23	BCL2 like 11	Homo sapiens	161-164
27557477-0	2017	Effect of proinflammatory cytokine IL-6 on efflux transport of rebamipide in Caco-2 cells.	rebamipide	63-73	interleukin 6	Homo sapiens	35-39
28983630-3	2017	The present study investigated whether rebamipide (Reb) acts as a secretagogue of intestinal mucin and the underlying mechanisms involved, thereby focusing on the effect on goblet cells.	rebamipide	39-49	LOC100508689	Homo sapiens	93-98
27557477-2	2017	Effect of IL-6, a pro-inflammatory cytokine, on efflux transport of rebamipide, an antiulcer drug, was investigated in Caco-2 cells.	rebamipide	68-78	interleukin 6	Homo sapiens	10-14
27557477-5	2017	Efflux transport of rebamipide was inhibited by cyclosporine A, a P-gp inhibitor, and probenecid, which is a general MRP inhibitor, but not by Ko143, a BCRP inhibitor.	rebamipide	20-30	phosphoglycolate phosphatase	Homo sapiens	66-70
27557477-5	2017	Efflux transport of rebamipide was inhibited by cyclosporine A, a P-gp inhibitor, and probenecid, which is a general MRP inhibitor, but not by Ko143, a BCRP inhibitor.	rebamipide	20-30	MARCKS like 1	Homo sapiens	117-120
27557477-10	2017	Therefore, it was suggested that increase of MRP(s)-mediated transport compensates for the decrease of P-gp mediated transport of rebamipide.	rebamipide	130-140	MARCKS like 1	Homo sapiens	45-48
27557477-10	2017	Therefore, it was suggested that increase of MRP(s)-mediated transport compensates for the decrease of P-gp mediated transport of rebamipide.	rebamipide	130-140	phosphoglycolate phosphatase	Homo sapiens	103-107
28011266-0	2017	Rebamipide induces the gastric mucosal protective factor, cyclooxygenase-2, via activation of 5"-AMP-activated protein kinase.	rebamipide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	58-74
28526636-10	2017	The levels of proinflammatory cytokines and matrix metallopeptidase 9 (MMP9) were significantly reduced upon rebamipide administration.	rebamipide	109-119	matrix metallopeptidase 9	Mus musculus	44-69
28526636-10	2017	The levels of proinflammatory cytokines and matrix metallopeptidase 9 (MMP9) were significantly reduced upon rebamipide administration.	rebamipide	109-119	matrix metallopeptidase 9	Mus musculus	71-75
28526636-11	2017	Intestinal cell proliferation and beta-catenin expression also increased upon rebamipide administration.	rebamipide	78-88	catenin (cadherin associated protein), beta 1	Mus musculus	34-46
28526636-12	2017	These data demonstrate that rebamipide reverses impairment of the intestinal barrier by increasing intestinal cell proliferation and attenuating the inflammatory response by inhibiting MMP9 and proinflammatory cytokine expression in a murine model of radiation-induced enteritis.	rebamipide	28-38	matrix metallopeptidase 9	Mus musculus	185-189
28587435-1	2017	It has been demonstrated that topical administration of rebamipide, which is an antiulcer agent, increases the mucin level of the tear film and ameliorates ocular surface conditions such as lid wiper epitheliopathy.	rebamipide	56-66	LOC100508689	Homo sapiens	111-116
28587435-2	2017	The aim of the present study was to analyze the changes in goblet cell number, cell proliferation, and epidermal growth factor receptor (EGFR) induced by topical rebamipide addition to the lid wiper of humans.	rebamipide	162-172	epidermal growth factor receptor	Homo sapiens	103-135
28587435-2	2017	The aim of the present study was to analyze the changes in goblet cell number, cell proliferation, and epidermal growth factor receptor (EGFR) induced by topical rebamipide addition to the lid wiper of humans.	rebamipide	162-172	epidermal growth factor receptor	Homo sapiens	137-141
28587435-10	2017	Immunohistochemistry revealed that EGFR levels in the lid wiper epithelial cells were significantly higher in the rebamipide group compared with the non-rebamipide group (P=0.0237).	rebamipide	114-124	epidermal growth factor receptor	Homo sapiens	35-39
28587435-10	2017	Immunohistochemistry revealed that EGFR levels in the lid wiper epithelial cells were significantly higher in the rebamipide group compared with the non-rebamipide group (P=0.0237).	rebamipide	153-163	epidermal growth factor receptor	Homo sapiens	35-39
28587435-11	2017	These results suggest that topical rebamipide application increases the number of goblet cells in the lid wiper, which in turn upregulates the expression of EGFR.	rebamipide	35-45	epidermal growth factor receptor	Homo sapiens	157-161
28241014-1	2017	RESULTS: The oral administration of rebamipide decreased plaque formation in atherosclerotic lesions as well as the markers of metabolic disorder in ApoE-deficient mice with atherosclerosis.	rebamipide	36-46	apolipoprotein E	Mus musculus	149-153
28241014-3	2017	In addition, the population of Th17 was decreased, whereas Treg was increased in the spleen of rebamipide-treated ApoE deficient mice.	rebamipide	95-105	apolipoprotein E	Mus musculus	114-118
28011266-2	2017	Induction of cyclooxygenase (COX)-2, a gastric mucosal protective factor, by rebamipide has been suggested as the major mechanism of the drug action.	rebamipide	77-87	cytochrome c oxidase II, mitochondrial	Mus musculus	13-35
28011266-3	2017	However, how rebamipide induces COX-2 at the molecular level needs further investigation.	rebamipide	13-23	cytochrome c oxidase II, mitochondrial	Mus musculus	32-37
28011266-4	2017	In this study, the molecular mechanism underlying the induction of COX-2 by rebamipide was investigated.	rebamipide	76-86	cytochrome c oxidase II, mitochondrial	Mus musculus	67-72
28011266-6	2017	The induction of COX-2 by rebamipide was dependent on AMPK activation because compound C, an AMPK inhibitor, abolished COX-2 induction by rebamipide.	rebamipide	26-36	cytochrome c oxidase II, mitochondrial	Mus musculus	17-22
28011266-6	2017	The induction of COX-2 by rebamipide was dependent on AMPK activation because compound C, an AMPK inhibitor, abolished COX-2 induction by rebamipide.	rebamipide	26-36	cytochrome c oxidase II, mitochondrial	Mus musculus	119-124
28011266-6	2017	The induction of COX-2 by rebamipide was dependent on AMPK activation because compound C, an AMPK inhibitor, abolished COX-2 induction by rebamipide.	rebamipide	138-148	cytochrome c oxidase II, mitochondrial	Mus musculus	17-22
28011266-6	2017	The induction of COX-2 by rebamipide was dependent on AMPK activation because compound C, an AMPK inhibitor, abolished COX-2 induction by rebamipide.	rebamipide	138-148	cytochrome c oxidase II, mitochondrial	Mus musculus	119-124
28011266-7	2017	In a mouse ulcer model, rebamipide protected against hydrochloric acid/ethanol-induced gastric ulcer, and these protective effects were deterred by co-administration of compound C. In parallel, in the gastric tissues, rebamipide increased the phosphorylation AMPK, whereas compound C reduced the levels of COX-2 and phosphorylated ACC, which were increased by rebamipide.	rebamipide	24-34	cytochrome c oxidase II, mitochondrial	Mus musculus	306-311
28011266-7	2017	In a mouse ulcer model, rebamipide protected against hydrochloric acid/ethanol-induced gastric ulcer, and these protective effects were deterred by co-administration of compound C. In parallel, in the gastric tissues, rebamipide increased the phosphorylation AMPK, whereas compound C reduced the levels of COX-2 and phosphorylated ACC, which were increased by rebamipide.	rebamipide	218-228	cytochrome c oxidase II, mitochondrial	Mus musculus	306-311
28011266-7	2017	In a mouse ulcer model, rebamipide protected against hydrochloric acid/ethanol-induced gastric ulcer, and these protective effects were deterred by co-administration of compound C. In parallel, in the gastric tissues, rebamipide increased the phosphorylation AMPK, whereas compound C reduced the levels of COX-2 and phosphorylated ACC, which were increased by rebamipide.	rebamipide	218-228	cytochrome c oxidase II, mitochondrial	Mus musculus	306-311
28011266-8	2017	Taken together, the activation of AMPK by rebamipide may be a molecular mechanism that contributes to induction of COX-2, probably resulting in protection against gastric ulcers.	rebamipide	42-52	cytochrome c oxidase II, mitochondrial	Mus musculus	115-120
26849241-7	2016	The results indicated that treatment with rebamipide significantly inhibited CCl4-induced increases in serum ALT and AST and also reduced oxidative stress induced by CCl4.	rebamipide	42-52	C-C motif chemokine ligand 4	Rattus norvegicus	77-81
28458352-7	2017	The administration of this ultrafine rebamipide suspension (2%) increased the conjunctival mucin, which was comparable to the commercially available micro-particle suspension (2%).	rebamipide	37-47	LOC100508689	Homo sapiens	91-96
27725198-0	2016	Differential effect of rebamipide on transmembrane mucin biosynthesis in stratified ocular surface epithelial cells.	rebamipide	23-33	LOC100508689	Homo sapiens	51-56
27725198-4	2016	We find that the addition of rebamipide to corneal, but not conjunctival, epithelial cells increased MUC16 protein biosynthesis.	rebamipide	29-39	mucin 16, cell surface associated	Homo sapiens	101-106
27725198-6	2016	In these experiments, rebamipide had no effect on the expression levels of Notch intracellular domains, suggesting that the rebamipide-induced increase in MUC16 biosynthesis in differentiated corneal cultures is not regulated by Notch signaling.	rebamipide	124-134	mucin 16, cell surface associated	Homo sapiens	155-160
27725198-7	2016	Overall these findings indicate that rebamipide induces the differential upregulation of MUC16 in stratified cultures of human corneal epithelial cells, which may have implications to the proper restoration of barrier function in ocular surface disease.	rebamipide	37-47	mucin 16, cell surface associated	Homo sapiens	89-94
27552406-1	2016	PURPOSE: Researchers have hypothesized that treatment with cyclosporine A (CyA), interleukin-1 receptor antagonists (IL-1RA; e.g., anakinra), P2Y2 receptor agonists (e.g., uridine triphosphate; UTP), and rebamipide may alleviate human meibomian gland dysfunction (MGD) and/or dry eye disease.	rebamipide	204-214	interleukin 1 receptor antagonist	Homo sapiens	81-115
27552406-10	2016	Cylosporine A, IL-1RA, rebamipide, and bimatoprost significantly reduced the phosphorylation of AKT, as compared to control.	rebamipide	23-33	AKT serine/threonine kinase 1	Homo sapiens	96-99
26849241-7	2016	The results indicated that treatment with rebamipide significantly inhibited CCl4-induced increases in serum ALT and AST and also reduced oxidative stress induced by CCl4.	rebamipide	42-52	C-C motif chemokine ligand 4	Rattus norvegicus	166-170
26849241-9	2016	At the higher dose tested, rebamipide appeared to be able to permit the hosts to have a normal liver histology and to minimize any CCl4-induced collagen precipitation in the liver.	rebamipide	27-37	C-C motif chemokine ligand 4	Rattus norvegicus	131-135
26849241-10	2016	Lastly, the use of rebamipide was seen to be associated with significant increases in liver levels of both PGE2 and the anti-inflammatory cytokine IL-10.	rebamipide	19-29	interleukin 10	Rattus norvegicus	147-152
26849241-11	2016	Based on these findings, it is concluded that rebamipide can retard hepatic fibrosis induced by CCl4 and that this effect may, in part, be mediated by an induction of PGE2 and IL-10 in the liver itself.	rebamipide	46-56	C-C motif chemokine ligand 4	Rattus norvegicus	96-100
26849241-11	2016	Based on these findings, it is concluded that rebamipide can retard hepatic fibrosis induced by CCl4 and that this effect may, in part, be mediated by an induction of PGE2 and IL-10 in the liver itself.	rebamipide	46-56	interleukin 10	Rattus norvegicus	176-181
27194990-5	2016	Subjective symptoms and expression levels of ocular surface mucin improved after combined treatment of rebamipide (4 times daily) and fluorometholone (once daily) ophthalmic suspension.	rebamipide	103-113	LOC100508689	Homo sapiens	60-65
27350608-12	2016	IL-17 and TNF-alpha expression in the spine, peripheral joints, and gut was lower in rebamipide-treated mice than in control mice.	rebamipide	85-95	interleukin 17A	Mus musculus	0-5
27350608-12	2016	IL-17 and TNF-alpha expression in the spine, peripheral joints, and gut was lower in rebamipide-treated mice than in control mice.	rebamipide	85-95	tumor necrosis factor	Mus musculus	10-19
27257394-1	2016	OBJECTIVE: Rebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epithelium.	rebamipide	11-21	LOC100508689	Homo sapiens	152-157
27257394-1	2016	OBJECTIVE: Rebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epithelium.	rebamipide	11-21	LOC100508689	Homo sapiens	196-201
27194990-8	2016	Subjective symptoms and expression levels of ocular surface mucin improved by combined treatment of rebamipide (4 times daily) and fluorometholone (once daily) ophthalmic suspension.	rebamipide	100-110	LOC100508689	Homo sapiens	60-65
26454448-1	2016	This study investigated the effect of rebamipide on activation of the NLRP3 inflammasome and generation of reactive oxygen species (ROS) in monosodium urate (MSU) crystal-induced interleukin-1beta (IL-1beta) production.	rebamipide	38-48	interleukin 1 beta	Homo sapiens	198-206
27123995-0	2016	Rebamipide Attenuates Mandibular Condylar Degeneration in a Murine Model of TMJ-OA by Mediating a Chondroprotective Effect and by Downregulating RANKL-Mediated Osteoclastogenesis.	rebamipide	0-10	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	145-150
27123995-7	2016	Rebamipide treatment was found to attenuate cartilage degeneration, to reduce the number of apoptotic cells, and to decrease the expression levels of matrix metalloproteinase-13 (MMP-13) and inducible nitric oxide synthase (iNOS) in TMJ-OA cartilage in a dose-dependent manner.	rebamipide	0-10	matrix metallopeptidase 13	Mus musculus	150-177
27123995-7	2016	Rebamipide treatment was found to attenuate cartilage degeneration, to reduce the number of apoptotic cells, and to decrease the expression levels of matrix metalloproteinase-13 (MMP-13) and inducible nitric oxide synthase (iNOS) in TMJ-OA cartilage in a dose-dependent manner.	rebamipide	0-10	matrix metallopeptidase 13	Mus musculus	179-185
27123995-7	2016	Rebamipide treatment was found to attenuate cartilage degeneration, to reduce the number of apoptotic cells, and to decrease the expression levels of matrix metalloproteinase-13 (MMP-13) and inducible nitric oxide synthase (iNOS) in TMJ-OA cartilage in a dose-dependent manner.	rebamipide	0-10	nitric oxide synthase 2, inducible	Mus musculus	191-222
27123995-8	2016	Rebamipide also suppressed the activation of transcription factors (e.g., NF-kappaB, NFATc1) and mitogen-activated protein kinases (MAPK) by receptor activator of nuclear factor kappa-B ligand (RANKL) to inhibit the differentiation of osteoclastic precursors, and disrupted the formation of actin rings in mature osteoclasts.	rebamipide	0-10	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	85-91
27123995-8	2016	Rebamipide also suppressed the activation of transcription factors (e.g., NF-kappaB, NFATc1) and mitogen-activated protein kinases (MAPK) by receptor activator of nuclear factor kappa-B ligand (RANKL) to inhibit the differentiation of osteoclastic precursors, and disrupted the formation of actin rings in mature osteoclasts.	rebamipide	0-10	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	141-192
27123995-8	2016	Rebamipide also suppressed the activation of transcription factors (e.g., NF-kappaB, NFATc1) and mitogen-activated protein kinases (MAPK) by receptor activator of nuclear factor kappa-B ligand (RANKL) to inhibit the differentiation of osteoclastic precursors, and disrupted the formation of actin rings in mature osteoclasts.	rebamipide	0-10	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	194-199
26454448-0	2016	Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1beta Production Through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells.	rebamipide	0-10	interleukin 1 beta	Homo sapiens	55-72
26454448-0	2016	Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1beta Production Through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells.	rebamipide	0-10	caspase 1	Homo sapiens	127-136
26454448-0	2016	Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1beta Production Through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells.	rebamipide	0-10	GLI family zinc finger 2	Homo sapiens	140-145
26454448-1	2016	This study investigated the effect of rebamipide on activation of the NLRP3 inflammasome and generation of reactive oxygen species (ROS) in monosodium urate (MSU) crystal-induced interleukin-1beta (IL-1beta) production.	rebamipide	38-48	NLR family pyrin domain containing 3	Homo sapiens	70-75
26454448-1	2016	This study investigated the effect of rebamipide on activation of the NLRP3 inflammasome and generation of reactive oxygen species (ROS) in monosodium urate (MSU) crystal-induced interleukin-1beta (IL-1beta) production.	rebamipide	38-48	interleukin 1 beta	Homo sapiens	179-196
26454448-6	2016	In THP-1 cells, treatment with MSU crystals increased NADP/NADPH ratios and IL-1beta expression, and both of these responses were potently inhibited by addition of rebamipide.	rebamipide	164-174	GLI family zinc finger 2	Homo sapiens	3-8
26454448-6	2016	In THP-1 cells, treatment with MSU crystals increased NADP/NADPH ratios and IL-1beta expression, and both of these responses were potently inhibited by addition of rebamipide.	rebamipide	164-174	interleukin 1 beta	Homo sapiens	76-84
26454448-7	2016	Rebamipide also attenuated enhanced expression of caspase-1 gene by MSU crystals (p &lt; 0.05).	rebamipide	0-10	caspase 1	Homo sapiens	50-59
26454448-9	2016	Similarly, MSU crystals activated the NF-kappaB pathway, which in turn was blocked by rebamipide.	rebamipide	86-96	nuclear factor kappa B subunit 1	Homo sapiens	38-47
26454448-10	2016	Stimulation of HUVECs with MSU crystals increased expression of VCAM-1 and ICAM-1, which were markedly inhibited by both rebamipide and dexamethasone.	rebamipide	121-131	vascular cell adhesion molecule 1	Homo sapiens	64-70
26454448-10	2016	Stimulation of HUVECs with MSU crystals increased expression of VCAM-1 and ICAM-1, which were markedly inhibited by both rebamipide and dexamethasone.	rebamipide	121-131	intercellular adhesion molecule 1	Homo sapiens	75-81
26454448-11	2016	This study demonstrated that rebamipide inhibits IL-1beta activation through suppression of ROS-mediated NF-kappaB signaling pathways and caspase-1 activation in MSU crystal-induced inflammation.	rebamipide	29-39	interleukin 1 beta	Homo sapiens	49-57
26454448-11	2016	This study demonstrated that rebamipide inhibits IL-1beta activation through suppression of ROS-mediated NF-kappaB signaling pathways and caspase-1 activation in MSU crystal-induced inflammation.	rebamipide	29-39	nuclear factor kappa B subunit 1	Homo sapiens	105-114
26454448-11	2016	This study demonstrated that rebamipide inhibits IL-1beta activation through suppression of ROS-mediated NF-kappaB signaling pathways and caspase-1 activation in MSU crystal-induced inflammation.	rebamipide	29-39	caspase 1	Homo sapiens	138-147
26135128-0	2015	Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of beta-Catenin.	rebamipide	0-10	catenin (cadherin associated protein), beta 1	Mus musculus	111-123
26472814-2	2015	A previous report showed that rebamipide improved asthmatic symptoms in an ovalbumin/trypsin mice model.	rebamipide	30-40	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	75-84
26472814-6	2015	In addition to these anti-inflammatory effects, rebamipide inhibited the production of IL-33, a member of the IL-1 family that drives the subsequent production of Th2-associated cytokines.	rebamipide	48-58	interleukin 33	Mus musculus	87-92
26472814-6	2015	In addition to these anti-inflammatory effects, rebamipide inhibited the production of IL-33, a member of the IL-1 family that drives the subsequent production of Th2-associated cytokines.	rebamipide	48-58	heart and neural crest derivatives expressed 2	Mus musculus	163-166
26369655-9	2015	The percentages of CDX2 (31.5 vs. 15.7%, P = 0.021) and TFF3 (44.9 vs. 25.8%, P = 0.012) expressing gastric mucosa cells were significantly lower after rebamipide medication than pre-treatment values.	rebamipide	152-162	caudal type homeobox 2	Homo sapiens	19-23
26369655-9	2015	The percentages of CDX2 (31.5 vs. 15.7%, P = 0.021) and TFF3 (44.9 vs. 25.8%, P = 0.012) expressing gastric mucosa cells were significantly lower after rebamipide medication than pre-treatment values.	rebamipide	152-162	trefoil factor 3	Homo sapiens	56-60
26369655-10	2015	CONCLUSIONS: Rebamipide improved the clinical symptoms, gastric mucosal lesions, and pathological grades of chronic gastritis patients and decreased the expression rates of CDX2 and TFF3 in gastric cells.	rebamipide	13-23	caudal type homeobox 2	Homo sapiens	173-177
26369655-10	2015	CONCLUSIONS: Rebamipide improved the clinical symptoms, gastric mucosal lesions, and pathological grades of chronic gastritis patients and decreased the expression rates of CDX2 and TFF3 in gastric cells.	rebamipide	13-23	trefoil factor 3	Homo sapiens	182-186
26135128-12	2015	The expressions of COX-2, beta-catenin, and c-myc and the PGE2 concentrations in small intestinal tissues were significantly increased in mice with rebamipide treatments (P &lt; 0.05).	rebamipide	148-158	cytochrome c oxidase II, mitochondrial	Mus musculus	19-24
26135128-12	2015	The expressions of COX-2, beta-catenin, and c-myc and the PGE2 concentrations in small intestinal tissues were significantly increased in mice with rebamipide treatments (P &lt; 0.05).	rebamipide	148-158	catenin (cadherin associated protein), beta 1	Mus musculus	26-38
26135128-13	2015	CONCLUSION: Rebamipide administration in aspirin-induced SII mice could improve the intestinal barrier structure and promote the regeneration of small intestinal epithelial injury through up-regulating COX-2 expression and the accumulation of beta-catenin.	rebamipide	12-22	cytochrome c oxidase II, mitochondrial	Mus musculus	202-207
26135128-13	2015	CONCLUSION: Rebamipide administration in aspirin-induced SII mice could improve the intestinal barrier structure and promote the regeneration of small intestinal epithelial injury through up-regulating COX-2 expression and the accumulation of beta-catenin.	rebamipide	12-22	catenin (cadherin associated protein), beta 1	Mus musculus	243-255
25138760-8	2014	RESULTS: Rebamipide suppressed the release of interleukin (IL)-8 and the upregulation of IL-8 mRNA induced by tumour necrosis factor alpha (TNF-alpha) or LPS in corneal fibroblasts.	rebamipide	9-19	C-X-C motif chemokine ligand 8	Homo sapiens	46-64
25747976-10	2015	Rebamipide reduced the expression of iNOS and TGF-beta1, apoptosis, macrophage accumulation, serum TNF-alpha levels, and prevented reductions in serum and tissue glutathione (GSH) levels by 5-FU administration.	rebamipide	0-10	nitric oxide synthase 2, inducible	Mus musculus	37-41
25747976-10	2015	Rebamipide reduced the expression of iNOS and TGF-beta1, apoptosis, macrophage accumulation, serum TNF-alpha levels, and prevented reductions in serum and tissue glutathione (GSH) levels by 5-FU administration.	rebamipide	0-10	transforming growth factor, beta 1	Mus musculus	46-55
25747976-10	2015	Rebamipide reduced the expression of iNOS and TGF-beta1, apoptosis, macrophage accumulation, serum TNF-alpha levels, and prevented reductions in serum and tissue glutathione (GSH) levels by 5-FU administration.	rebamipide	0-10	tumor necrosis factor	Mus musculus	99-108
25817390-0	2015	Rebamipide suppresses TNF-alpha mediated inflammation in vitro and attenuates the severity of dermatitis in mice.	rebamipide	0-10	tumor necrosis factor	Mus musculus	22-31
25817390-4	2015	Here, we found that rebamipide alleviated the inflammatory reaction induced by tumor necrosis factor-alpha in RAW264.7, a stable macrophage cell line.	rebamipide	20-30	tumor necrosis factor	Mus musculus	79-106
26023912-2	2015	Rebamipide, an amino acid modified hydroxylquinoline, can alter the expression of key mediators of bone anabolism, cyclo-oxygenase 2 (COX-2), BMP-2 and vascular endothelial growth factor (VEGF), in diverse cell types such as mucosal and endothelial cells or chondrocytes.	rebamipide	0-10	bone morphogenetic protein 2	Homo sapiens	142-147
26023912-2	2015	Rebamipide, an amino acid modified hydroxylquinoline, can alter the expression of key mediators of bone anabolism, cyclo-oxygenase 2 (COX-2), BMP-2 and vascular endothelial growth factor (VEGF), in diverse cell types such as mucosal and endothelial cells or chondrocytes.	rebamipide	0-10	vascular endothelial growth factor A	Homo sapiens	152-186
26023912-2	2015	Rebamipide, an amino acid modified hydroxylquinoline, can alter the expression of key mediators of bone anabolism, cyclo-oxygenase 2 (COX-2), BMP-2 and vascular endothelial growth factor (VEGF), in diverse cell types such as mucosal and endothelial cells or chondrocytes.	rebamipide	0-10	vascular endothelial growth factor A	Homo sapiens	188-192
25574215-1	2015	The topical administration of rebamipide (Mucosta ), an antiulcer agent, clinically increases the mucin level of tear film.	rebamipide	30-40	LOC100508689	Homo sapiens	98-103
25574215-7	2015	By contrast, the secondary resected specimen obtained three months after the initiation of topical rebamipide treatment revealed the epithelium and nevus, where numerous goblet cells were present (28 cells/HPF), and mucin-like substances were markedly secreted from the goblet cells.	rebamipide	99-109	LOC100508689	Homo sapiens	216-221
25834302-7	2015	Rebamipide suppressed the upregulated gene expression of TNFalpha and Duox2 in a dose-dependent manner.	rebamipide	0-10	tumor necrosis factor	Rattus norvegicus	57-65
25834302-7	2015	Rebamipide suppressed the upregulated gene expression of TNFalpha and Duox2 in a dose-dependent manner.	rebamipide	0-10	dual oxidase 2	Rattus norvegicus	70-75
25138760-8	2014	RESULTS: Rebamipide suppressed the release of interleukin (IL)-8 and the upregulation of IL-8 mRNA induced by tumour necrosis factor alpha (TNF-alpha) or LPS in corneal fibroblasts.	rebamipide	9-19	C-X-C motif chemokine ligand 8	Homo sapiens	89-93
25138760-8	2014	RESULTS: Rebamipide suppressed the release of interleukin (IL)-8 and the upregulation of IL-8 mRNA induced by tumour necrosis factor alpha (TNF-alpha) or LPS in corneal fibroblasts.	rebamipide	9-19	tumor necrosis factor	Homo sapiens	140-149
25138760-10	2014	In addition, rebamipide attenuated the degradation of IkappaBalpha induced by TNF-alpha or LPS.	rebamipide	13-23	NFKB inhibitor alpha	Homo sapiens	54-66
25138760-10	2014	In addition, rebamipide attenuated the degradation of IkappaBalpha induced by TNF-alpha or LPS.	rebamipide	13-23	tumor necrosis factor	Homo sapiens	78-87
25138760-11	2014	CONCLUSIONS: Rebamipide inhibited the synthesis of chemokines by corneal fibroblasts in association with suppression of NFkappaB signalling.	rebamipide	13-23	nuclear factor kappa B subunit 1	Homo sapiens	120-128
24757140-10	2014	Rebamipide-treated mice showed lower circulating levels of type II collagen-specific IgG, IgG1, and IgG2a.	rebamipide	0-10	immunoglobulin heavy variable V1-9	Mus musculus	100-105
25705372-0	2014	Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops.	rebamipide	114-124	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
25705372-0	2014	Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops.	rebamipide	114-124	ribonuclease A family member 3	Homo sapiens	24-27
25705372-0	2014	Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops.	rebamipide	114-124	immunoglobulin heavy constant epsilon	Homo sapiens	39-42
25705372-4	2014	In the current study we examined the effect of rebamipide eyedrops on the level of interleukin-8 (IL-8), eosinophil cationic protein (ECP), and total IgE on the ocular surface.	rebamipide	47-57	C-X-C motif chemokine ligand 8	Homo sapiens	83-96
25705372-7	2014	The level of IL-8, ECP, and total IgE in the tears of AKC patients was reduced significantly 4-6 weeks after the start of rebamipide treatment.	rebamipide	122-132	C-X-C motif chemokine ligand 8	Homo sapiens	13-17
25705372-7	2014	The level of IL-8, ECP, and total IgE in the tears of AKC patients was reduced significantly 4-6 weeks after the start of rebamipide treatment.	rebamipide	122-132	ribonuclease A family member 3	Homo sapiens	19-22
25705372-7	2014	The level of IL-8, ECP, and total IgE in the tears of AKC patients was reduced significantly 4-6 weeks after the start of rebamipide treatment.	rebamipide	122-132	immunoglobulin heavy constant epsilon	Homo sapiens	34-37
24930516-9	2014	Treatment with rebamipide significantly decreased both the ROS concentration and the number of dying cells: this drug is prescribed clinically for gastric injury patients and has been reported to upregulate the expression of manganese superoxide dismutase.	rebamipide	15-25	superoxide dismutase 2	Homo sapiens	225-255
24940041-3	2014	Investigations have confirmed that rebamipide increases corneal and conjunctival mucin-like substances along with improving corneal and conjunctival injury.	rebamipide	35-45	LOC100508689	Homo sapiens	81-86
24940041-4	2014	Clinically, rebamipide ophthalmic suspensions can effectively treat tear deficiency and mucin-caused corneal epithelial damage, and can restore the microstructure responsible for tear stability.	rebamipide	12-22	LOC100508689	Homo sapiens	88-93
24757140-0	2014	Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of th17/treg cell differentiation and heme oxygenase 1 induction.	rebamipide	0-10	heme oxygenase 1	Mus musculus	117-133
24757140-10	2014	Rebamipide-treated mice showed lower circulating levels of type II collagen-specific IgG, IgG1, and IgG2a.	rebamipide	0-10	LOC105243590	Mus musculus	90-94
24757140-12	2014	In vitro, rebamipide inhibited Th17 cell differentiation through STAT-3/retinoic acid receptor-related orphan nuclear receptor gammat and reciprocally induced Treg cell differentiation through FoxP3.	rebamipide	10-20	forkhead box P3	Mus musculus	193-198
24757140-14	2014	Heme oxygenase 1 (HO-1) expression in the spleens was markedly increased in rebamipide-treated mice.	rebamipide	76-86	heme oxygenase 1	Mus musculus	0-16
24757140-14	2014	Heme oxygenase 1 (HO-1) expression in the spleens was markedly increased in rebamipide-treated mice.	rebamipide	76-86	heme oxygenase 1	Mus musculus	18-22
24757140-15	2014	CONCLUSION: The inhibitory effects of rebamipide on joint inflammation are associated with recovery from an imbalance between Th17 cells and Treg cells and with activation of an Nrf2/HO-1 antioxidant pathway.	rebamipide	38-48	nuclear factor, erythroid derived 2, like 2	Mus musculus	178-182
24757140-15	2014	CONCLUSION: The inhibitory effects of rebamipide on joint inflammation are associated with recovery from an imbalance between Th17 cells and Treg cells and with activation of an Nrf2/HO-1 antioxidant pathway.	rebamipide	38-48	heme oxygenase 1	Mus musculus	183-187
23428631-0	2013	Rebamipide inhibits indomethacin-induced small intestinal injury: possible involvement of intestinal microbiota modulation by upregulation of alpha-defensin 5.	rebamipide	0-10	defensin, alpha, 5	Mus musculus	142-158
24073690-4	2014	In this study, we investigated the effect of rebamipide on the regulation of MAM expression in HCE cells.	rebamipide	45-55	sarcoglycan gamma	Homo sapiens	77-80
24073690-8	2014	Western blot analysis of cells treated with an EGF receptor inhibitor (AG1478) or MEK1/2 inhibitor (U0126) was performed to reveal the relationship between EGF receptor activation and rebamipide-induced MAM expression.	rebamipide	184-194	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
24073690-8	2014	Western blot analysis of cells treated with an EGF receptor inhibitor (AG1478) or MEK1/2 inhibitor (U0126) was performed to reveal the relationship between EGF receptor activation and rebamipide-induced MAM expression.	rebamipide	184-194	epidermal growth factor	Homo sapiens	156-159
24073690-8	2014	Western blot analysis of cells treated with an EGF receptor inhibitor (AG1478) or MEK1/2 inhibitor (U0126) was performed to reveal the relationship between EGF receptor activation and rebamipide-induced MAM expression.	rebamipide	184-194	sarcoglycan gamma	Homo sapiens	203-206
24073690-11	2014	EGF inhibitor treatment led to reduced levels of all three MAMs that are normally induced by rebamipide, whereas EGF induced the expression of all three MAMs.	rebamipide	93-103	epidermal growth factor	Homo sapiens	0-3
24073690-13	2014	These data suggest that rebamipide may improve subjective symptoms of dry eye disease by upregulating MAM expression.	rebamipide	24-34	sarcoglycan gamma	Homo sapiens	102-105
23306427-0	2013	The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group.	rebamipide	16-26	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	69-74
23306427-10	2013	Rebamipide might be a candidate for an option to prevent COX-2 selective inhibitor-induced upper GI events.	rebamipide	0-10	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	57-62
22890316-7	2013	Rebamipide, a mucosal-protective antiulcer agent, abolished H. pylori cagA-induced PLD1 expression via inhibition of binding of NFkappaB to the PLD1 promoter, and also inhibited PLD activity.	rebamipide	0-10	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	83-86
24262494-10	2014	Up-regulated myeloperoxidase, IL-1beta, IL-6 and TNF-alpha expression in cyclophosphamide treated rats was also suppressed in rebamipide treated rats.	rebamipide	126-136	myeloperoxidase	Rattus norvegicus	13-28
24262494-10	2014	Up-regulated myeloperoxidase, IL-1beta, IL-6 and TNF-alpha expression in cyclophosphamide treated rats was also suppressed in rebamipide treated rats.	rebamipide	126-136	interleukin 1 beta	Rattus norvegicus	30-38
24262494-10	2014	Up-regulated myeloperoxidase, IL-1beta, IL-6 and TNF-alpha expression in cyclophosphamide treated rats was also suppressed in rebamipide treated rats.	rebamipide	126-136	interleukin 6	Rattus norvegicus	40-44
24262494-10	2014	Up-regulated myeloperoxidase, IL-1beta, IL-6 and TNF-alpha expression in cyclophosphamide treated rats was also suppressed in rebamipide treated rats.	rebamipide	126-136	tumor necrosis factor	Rattus norvegicus	49-58
24168989-1	2013	PURPOSE: To investigate the efficacy of 2% rebamipide ophthalmic solution on the tear functions and ocular surface status of the superoxide dismutase-1(Sod1(-/-)) mice.	rebamipide	43-53	superoxide dismutase 1, soluble	Mus musculus	129-151
24168989-6	2013	Application of 2% rebamipide for 2 weeks significantly improved the tear film break-up time, the amount of tear production, and the corneal epithelial damage scores, which also significantly increased the conjunctival goblet cell density and muc5 mRNA expression, in the Sod1(-/-) mice.	rebamipide	18-28	mucin 5, subtype B, tracheobronchial	Mus musculus	242-246
24168989-6	2013	Application of 2% rebamipide for 2 weeks significantly improved the tear film break-up time, the amount of tear production, and the corneal epithelial damage scores, which also significantly increased the conjunctival goblet cell density and muc5 mRNA expression, in the Sod1(-/-) mice.	rebamipide	18-28	superoxide dismutase 1, soluble	Mus musculus	271-275
24168989-8	2013	CONCLUSIONS: Two percent Rebamipide ophthalmic solution significantly improved the tear stability and corneal epithelial damage, and enhanced the expression of muc5 mRNA on the ocular surface.	rebamipide	25-35	mucin 5, subtype B, tracheobronchial	Mus musculus	160-164
24168989-9	2013	We also observed anti-inflammatory effects in the tear film together with antioxidative effects in the conjunctiva, suggesting the efficacy of rebamipide in age-related dry eye disease attributable to SOD1 knockout.	rebamipide	143-153	superoxide dismutase 1, soluble	Mus musculus	201-205
23662915-3	2013	The eyedrop form of rebamipide, approved in Japan for use in the treatment of dry eye diseases, upregulates mucin secretion and production, thereby suppressing superficial punctate keratopathy on the ocular surface of patients with this disease.	rebamipide	20-30	LOC100508689	Homo sapiens	108-113
23662915-7	2013	RESULTS: Rebamipide could suppress polyI:C-induced cytokine production and the expression of mRNAs for CXCL10, CXCL11, RANTES, MCP-1, and IL-6 in human conjunctival epithelial cells.	rebamipide	9-19	C-X-C motif chemokine ligand 10	Homo sapiens	103-109
23662915-7	2013	RESULTS: Rebamipide could suppress polyI:C-induced cytokine production and the expression of mRNAs for CXCL10, CXCL11, RANTES, MCP-1, and IL-6 in human conjunctival epithelial cells.	rebamipide	9-19	C-X-C motif chemokine ligand 11	Homo sapiens	111-117
23662915-7	2013	RESULTS: Rebamipide could suppress polyI:C-induced cytokine production and the expression of mRNAs for CXCL10, CXCL11, RANTES, MCP-1, and IL-6 in human conjunctival epithelial cells.	rebamipide	9-19	C-C motif chemokine ligand 5	Homo sapiens	119-125
23662915-7	2013	RESULTS: Rebamipide could suppress polyI:C-induced cytokine production and the expression of mRNAs for CXCL10, CXCL11, RANTES, MCP-1, and IL-6 in human conjunctival epithelial cells.	rebamipide	9-19	C-C motif chemokine ligand 2	Homo sapiens	127-132
23662915-7	2013	RESULTS: Rebamipide could suppress polyI:C-induced cytokine production and the expression of mRNAs for CXCL10, CXCL11, RANTES, MCP-1, and IL-6 in human conjunctival epithelial cells.	rebamipide	9-19	interleukin 6	Homo sapiens	138-142
23603753-0	2013	Rebamipide increases barrier function and attenuates TNFalpha-induced barrier disruption and cytokine expression in human corneal epithelial cells.	rebamipide	0-10	tumor necrosis factor	Homo sapiens	53-61
23603753-7	2013	RESULTS: Rebamipide increased TER of HCE cells in a concentration-dependent manner as well as attenuating the loss of TER and the disappearance of ZO-1 from the cell surface induced by tumour necrosis factor alpha (TNFalpha).	rebamipide	9-19	tight junction protein 1	Homo sapiens	147-151
23603753-7	2013	RESULTS: Rebamipide increased TER of HCE cells in a concentration-dependent manner as well as attenuating the loss of TER and the disappearance of ZO-1 from the cell surface induced by tumour necrosis factor alpha (TNFalpha).	rebamipide	9-19	tumor necrosis factor	Homo sapiens	215-223
23603753-8	2013	Rebamipide also suppressed TNFalpha-induced expression of interleukin-6 and interleukin-8 at the mRNA and protein levels and inhibited the TNFalpha-induced degradation of IkappaBalpha.	rebamipide	0-10	tumor necrosis factor	Homo sapiens	27-35
23603753-8	2013	Rebamipide also suppressed TNFalpha-induced expression of interleukin-6 and interleukin-8 at the mRNA and protein levels and inhibited the TNFalpha-induced degradation of IkappaBalpha.	rebamipide	0-10	interleukin 6	Homo sapiens	58-71
23603753-8	2013	Rebamipide also suppressed TNFalpha-induced expression of interleukin-6 and interleukin-8 at the mRNA and protein levels and inhibited the TNFalpha-induced degradation of IkappaBalpha.	rebamipide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	76-89
23603753-8	2013	Rebamipide also suppressed TNFalpha-induced expression of interleukin-6 and interleukin-8 at the mRNA and protein levels and inhibited the TNFalpha-induced degradation of IkappaBalpha.	rebamipide	0-10	tumor necrosis factor	Homo sapiens	139-147
23603753-8	2013	Rebamipide also suppressed TNFalpha-induced expression of interleukin-6 and interleukin-8 at the mRNA and protein levels and inhibited the TNFalpha-induced degradation of IkappaBalpha.	rebamipide	0-10	NFKB inhibitor alpha	Homo sapiens	171-183
23482463-0	2013	Protection of human corneal epithelial cells from TNF-alpha-induced disruption of barrier function by rebamipide.	rebamipide	102-112	tumor necrosis factor	Homo sapiens	50-59
23482463-2	2013	We investigated the effects of the cytoprotective drug rebamipide on this barrier disruption by TNF-alpha as well as on corneal epithelial damage in a rat model of dry eye.	rebamipide	55-65	tumor necrosis factor	Rattus norvegicus	96-105
23482463-7	2013	RESULTS: Rebamipide inhibited the disruption of barrier function as well as the downregulation of ZO-1 expression, and the disappearance of ZO-1 from the interfaces of neighboring HCE cells induced by TNF-alpha.	rebamipide	9-19	tight junction protein 1	Homo sapiens	98-102
23482463-7	2013	RESULTS: Rebamipide inhibited the disruption of barrier function as well as the downregulation of ZO-1 expression, and the disappearance of ZO-1 from the interfaces of neighboring HCE cells induced by TNF-alpha.	rebamipide	9-19	tumor necrosis factor	Homo sapiens	201-210
23482463-9	2013	Treatment with rebamipide eyedrops promoted the healing of corneal epithelial defects as well as attenuated the loss of ZO-1 from the surface of corneal epithelial cells in rats.	rebamipide	15-25	tight junction protein 1	Rattus norvegicus	120-124
23482463-10	2013	CONCLUSIONS: Rebamipide protects corneal epithelial cells from the TNF-alpha-induced disruption of barrier function by maintaining the distribution and expression of ZO-1 as well as the organization of the actin cytoskeleton.	rebamipide	13-23	tumor necrosis factor	Homo sapiens	67-76
23482463-10	2013	CONCLUSIONS: Rebamipide protects corneal epithelial cells from the TNF-alpha-induced disruption of barrier function by maintaining the distribution and expression of ZO-1 as well as the organization of the actin cytoskeleton.	rebamipide	13-23	tight junction protein 1	Homo sapiens	166-170
23428631-7	2013	The mice that were treated with rebamipide showed an increase in alpha-defensin 5 mRNA expression and protein levels in the ileal tissue compared to vehicle-treated control mice.	rebamipide	32-42	defensin, alpha, 5	Mus musculus	65-81
23428631-8	2013	Indomethacin reduced expression of alpha-defensin 5 mRNA in ileal tissue, while rebamipide reversed expression of alpha-defensin 5 mRNA.	rebamipide	80-90	defensin, alpha, 5	Mus musculus	114-130
23428631-9	2013	In conclusion, our study results suggest that rebamipide inhibits indomethacin-induced small intestinal injuries, possibly by modulating microbiota in the small intestine by upregulation of alpha-defensin 5.	rebamipide	46-56	defensin, alpha, 5	Mus musculus	190-206
22890185-11	2012	By contrast, rebamipide induced the mRNA expression of tissue inhibitor of metalloproteinase-1 and -3.	rebamipide	13-23	TIMP metallopeptidase inhibitor 1	Rattus norvegicus	55-101
23338062-8	2013	Rebamipide reduced the expression of matrix metalloproteinase 13, interleukin-1beta, inducible nitric oxide synthase, and nitrotyrosine in OA cartilage.	rebamipide	0-10	matrix metallopeptidase 13	Rattus norvegicus	37-64
23338062-8	2013	Rebamipide reduced the expression of matrix metalloproteinase 13, interleukin-1beta, inducible nitric oxide synthase, and nitrotyrosine in OA cartilage.	rebamipide	0-10	interleukin 1 beta	Rattus norvegicus	66-83
22890185-8	2012	Rebamipide reduced the expression of MMP-13, IL-1beta, HIF-2alpha, iNOS, and nitrotyrosine in OA cartilage in a dose-dependent manner.	rebamipide	0-10	matrix metallopeptidase 13	Rattus norvegicus	37-43
22890185-8	2012	Rebamipide reduced the expression of MMP-13, IL-1beta, HIF-2alpha, iNOS, and nitrotyrosine in OA cartilage in a dose-dependent manner.	rebamipide	0-10	interleukin 1 beta	Rattus norvegicus	45-53
24204116-1	2013	Administration of topical rebamipide increases the mucin level of tear film and improves the ocular surface in short break-up time type of dry eye.	rebamipide	26-36	LOC100508689	Homo sapiens	51-56
22732404-0	2012	Rebamipide induces dendritic cell recruitment to N-methyl-N"-nitro-N-nitrosoguanidine (MNNG)-exposed rat gastric mucosa based on IL-1beta upregulation.	rebamipide	0-10	interleukin 1 beta	Rattus norvegicus	129-137
22890185-8	2012	Rebamipide reduced the expression of MMP-13, IL-1beta, HIF-2alpha, iNOS, and nitrotyrosine in OA cartilage in a dose-dependent manner.	rebamipide	0-10	endothelial PAS domain protein 1	Rattus norvegicus	55-65
22890185-8	2012	Rebamipide reduced the expression of MMP-13, IL-1beta, HIF-2alpha, iNOS, and nitrotyrosine in OA cartilage in a dose-dependent manner.	rebamipide	0-10	nitric oxide synthase 2	Rattus norvegicus	67-71
22732404-5	2012	However, after concurrent exposure to MNNG for 14 days, treatment with rebamipide slightly increased CD68-positive cells in the Lewis strain, and significantly increased them in the Buffalo strain.	rebamipide	71-81	Cd68 molecule	Rattus norvegicus	101-105
22653900-0	2012	Rebamipide attenuates nonsteroidal anti-inflammatory drugs (NSAID) induced lipid peroxidation by the manganese superoxide dismutase (MnSOD) overexpression in gastrointestinal epithelial cells.	rebamipide	0-10	superoxide dismutase 2	Rattus norvegicus	101-131
22732404-6	2012	Analysis of two chemotactic factors of dendritic cells, IL-1beta and TNF-alpha, in the gastric cancer cells showed that expression of IL-1beta, but not TNF-alpha, was induced by rebamipide in a dose-dependent manner.	rebamipide	178-188	interleukin 1 beta	Rattus norvegicus	56-64
22732404-6	2012	Analysis of two chemotactic factors of dendritic cells, IL-1beta and TNF-alpha, in the gastric cancer cells showed that expression of IL-1beta, but not TNF-alpha, was induced by rebamipide in a dose-dependent manner.	rebamipide	178-188	tumor necrosis factor	Rattus norvegicus	69-78
22732404-6	2012	Analysis of two chemotactic factors of dendritic cells, IL-1beta and TNF-alpha, in the gastric cancer cells showed that expression of IL-1beta, but not TNF-alpha, was induced by rebamipide in a dose-dependent manner.	rebamipide	178-188	interleukin 1 beta	Rattus norvegicus	134-142
22732404-8	2012	In conclusion, rebamipide has potential tumor-suppressive effects on gastric tumorigenesis via the recruitment of dendritic cells, based on the upregulation of the IL-1beta gene in gastric epithelial cells.	rebamipide	15-25	interleukin 1 beta	Rattus norvegicus	164-172
26182160-10	2012	Combination therapy with misoprostol and rebamipide may be useful for treating COX-2 selective inhibitor-induced anemia and small intestinal injuries.	rebamipide	41-51	prostaglandin-endoperoxide synthase 2	Homo sapiens	79-84
22335446-10	2012	CONCLUSIONS: Rebamipide promoted glycoconjugate, which has a property as a mucin-like glycoprotein, in human corneal epithelial cells.	rebamipide	13-23	LOC100508689	Homo sapiens	75-80
22653900-6	2012	We hypothesized that rebamipide may attenuate lipid peroxidation by increasing the expression of MnSOD protein in mitochondria and decreasing the leakage of superoxide anion in NSAID-treated gastric and small intestinal epithelial cells.	rebamipide	21-31	superoxide dismutase 2	Rattus norvegicus	97-102
22653900-7	2012	Firstly, to examine rebamipide increases the expression of MnSOD proteins in mitochondria of gastrointestinal epithelial cells, we underwent Western blotting analysis against anti-MnSOD antibody in gastric RGM1 cells and small intestinal IEC6 cells.	rebamipide	20-30	superoxide dismutase 2	Rattus norvegicus	59-64
22653900-7	2012	Firstly, to examine rebamipide increases the expression of MnSOD proteins in mitochondria of gastrointestinal epithelial cells, we underwent Western blotting analysis against anti-MnSOD antibody in gastric RGM1 cells and small intestinal IEC6 cells.	rebamipide	20-30	superoxide dismutase 2	Rattus norvegicus	180-185
22653900-10	2012	Rebamipide increased the expression of MnSOD protein, and attenuated NSAID-induced mitochondrial impairment and lipid peroxidation in RGM1 and IEC6 cells.	rebamipide	0-10	superoxide dismutase 2	Rattus norvegicus	39-44
22653900-12	2012	We conclude that rebamipide attenuates lipid peroxidation by increasing the expression of MnSOD protein and decreasing superoxide anion leakage from mitochondria in both gastric and small intestinal epithelial cells.	rebamipide	17-27	superoxide dismutase 2	Rattus norvegicus	90-95
22653900-0	2012	Rebamipide attenuates nonsteroidal anti-inflammatory drugs (NSAID) induced lipid peroxidation by the manganese superoxide dismutase (MnSOD) overexpression in gastrointestinal epithelial cells.	rebamipide	0-10	superoxide dismutase 2	Rattus norvegicus	133-138
21987622-8	2011	The wound assay revealed that rebamipide enhanced the migration of RIE cells through phosphorylation of extracellular signal-regulated kinase (ERK) and activation of Rho kinase.	rebamipide	30-40	Eph receptor B1	Rattus norvegicus	104-141
22416180-10	2012	Rebamipide significantly reduced intestinal permeability, improved inter-cellular tight junctions, and was associated with decreases in intestinal MDA content and MPO activity.	rebamipide	0-10	myeloperoxidase	Mus musculus	163-166
22416180-11	2012	At the mitochondrial level, rebamipide increased SDH and ATPase activities, NADH level and decreased mitochondrial swelling.	rebamipide	28-38	aminoadipate-semialdehyde synthase	Mus musculus	49-52
22969286-3	2012	The therapeutic effects of rebamipide eye drops are due to its ability to increase corneal and conjunctival mucin-like substances and improve corneal and conjunctival injury in vivo.	rebamipide	27-37	LOC100508689	Homo sapiens	108-113
21987622-8	2011	The wound assay revealed that rebamipide enhanced the migration of RIE cells through phosphorylation of extracellular signal-regulated kinase (ERK) and activation of Rho kinase.	rebamipide	30-40	Eph receptor B1	Rattus norvegicus	143-146
21987622-9	2011	CONCLUSION: Rebamipide enema healed intestinal injury by enhancing restitution of RIE cells, via ERK activation.	rebamipide	12-22	Eph receptor B1	Rattus norvegicus	97-100
20198424-10	2010	IL-8 mRNA expression in the esophageal mucosa of patients with rebamipide was significantly decreased compared with that of patients without rebamipide.	rebamipide	63-73	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
21373268-0	2011	Rebamipide, a mucoprotective drug, inhibits NSAIDs-induced gastric mucosal injury: possible involvement of the downregulation of 15-hydroxyprostaglandin dehydrogenase.	rebamipide	0-10	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	129-166
21373268-5	2011	Suppressive effect of rebamipide on indomethacin-induced gastric mucosal injury was also observed in cyclooxygenase-2-knockout mice.	rebamipide	22-32	prostaglandin-endoperoxide synthase 2	Mus musculus	101-117
21373268-6	2011	The mice that were treated with rebamipide showed a 2-fold increase in cyclooxygenase-2 mRNA expression in the gastric tissue, whereas 15-hydroxyprostaglandin dehydrogenase mRNA expression markedly decreased as compared to vehicle-treated control mice.	rebamipide	32-42	prostaglandin-endoperoxide synthase 2	Mus musculus	71-87
21373268-6	2011	The mice that were treated with rebamipide showed a 2-fold increase in cyclooxygenase-2 mRNA expression in the gastric tissue, whereas 15-hydroxyprostaglandin dehydrogenase mRNA expression markedly decreased as compared to vehicle-treated control mice.	rebamipide	32-42	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	135-172
21373268-9	2011	These results suggest that the suppressive effect of rebamipide on non-steroidal anti-inflammatory drugs-induced gastric mucosal injury can be attributed to reduced 15-hydroxyprostaglandin dehydrogenase expression, which increases the prostaglandin E(2) concentration in the gastric tissue.	rebamipide	53-63	hydroxyprostaglandin dehydrogenase 15 (NAD)	Mus musculus	165-202
21373269-0	2011	Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFN-alpha/beta reduction.	rebamipide	0-10	TANK binding kinase 1	Homo sapiens	26-30
21373269-0	2011	Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFN-alpha/beta reduction.	rebamipide	0-10	interferon regulatory factor 3	Homo sapiens	73-77
21373269-0	2011	Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFN-alpha/beta reduction.	rebamipide	0-10	interferon alpha 1	Homo sapiens	84-93
21373269-9	2011	Rebamipide reduced the expression of TBK1, IRF3 and IRF7 mRNA induced by LPS/dsRNA, but not of NF-kappaB mRNA in colonic epithelial cells.	rebamipide	0-10	TANK binding kinase 1	Homo sapiens	37-41
21373269-9	2011	Rebamipide reduced the expression of TBK1, IRF3 and IRF7 mRNA induced by LPS/dsRNA, but not of NF-kappaB mRNA in colonic epithelial cells.	rebamipide	0-10	interferon regulatory factor 3	Homo sapiens	43-47
21373269-9	2011	Rebamipide reduced the expression of TBK1, IRF3 and IRF7 mRNA induced by LPS/dsRNA, but not of NF-kappaB mRNA in colonic epithelial cells.	rebamipide	0-10	interferon regulatory factor 7	Homo sapiens	52-56
21373269-10	2011	Rebamipide might suppress the TLR-TBK1 pathway, resulting in IRF3/7-induction of IFN-alpha/beta and inflammatory factors.	rebamipide	0-10	TANK binding kinase 1	Homo sapiens	30-38
21373269-10	2011	Rebamipide might suppress the TLR-TBK1 pathway, resulting in IRF3/7-induction of IFN-alpha/beta and inflammatory factors.	rebamipide	0-10	interferon regulatory factor 3	Homo sapiens	61-65
21373269-10	2011	Rebamipide might suppress the TLR-TBK1 pathway, resulting in IRF3/7-induction of IFN-alpha/beta and inflammatory factors.	rebamipide	0-10	interferon alpha 1	Homo sapiens	81-90
21373269-12	2011	If rebamipide represses the TLR-TBK1 pathway, then rectal administration should suppress inflammation of the colonic mucosa in patients with UC.	rebamipide	3-13	TANK binding kinase 1	Homo sapiens	28-36
20556513-6	2011	Pre-treatment with rebamipide inhibits CagA-induced effects on gastric epithelial cells, including morphologic changes (hummingbird phenotype) associated with ZO-1 mislocalization, IL-8 production, and NF-kappaB activity.	rebamipide	19-29	C-X-C motif chemokine ligand 8	Canis lupus familiaris	181-185
20198424-10	2010	IL-8 mRNA expression in the esophageal mucosa of patients with rebamipide was significantly decreased compared with that of patients without rebamipide.	rebamipide	141-151	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
20625243-0	2010	Rebamipide-induced downregulation of phospholipase D inhibits inflammation and proliferation in gastric cancer cells.	rebamipide	0-10	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	37-52
20607584-0	2010	Rebamipide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression by suppressing the NF-kappaB signal pathway in human umbilical vein endothelial cells.	rebamipide	0-10	tumor necrosis factor	Homo sapiens	20-47
20607584-0	2010	Rebamipide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression by suppressing the NF-kappaB signal pathway in human umbilical vein endothelial cells.	rebamipide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	56-69
20607584-0	2010	Rebamipide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression by suppressing the NF-kappaB signal pathway in human umbilical vein endothelial cells.	rebamipide	0-10	nuclear factor kappa B subunit 1	Homo sapiens	100-109
20607584-1	2010	OBJECTIVE: This study was designed to identify the inhibitory effect of rebamipide on tumor necrosis factor-alpha (TNF-alpha)-induced interleukin-8 (IL-8) production and nuclear factor-kappaB (NF-kappaB) activation in human umbilical vein endothelial cells (HUVECs).	rebamipide	72-82	tumor necrosis factor	Homo sapiens	86-113
20607584-1	2010	OBJECTIVE: This study was designed to identify the inhibitory effect of rebamipide on tumor necrosis factor-alpha (TNF-alpha)-induced interleukin-8 (IL-8) production and nuclear factor-kappaB (NF-kappaB) activation in human umbilical vein endothelial cells (HUVECs).	rebamipide	72-82	tumor necrosis factor	Homo sapiens	115-124
20607584-1	2010	OBJECTIVE: This study was designed to identify the inhibitory effect of rebamipide on tumor necrosis factor-alpha (TNF-alpha)-induced interleukin-8 (IL-8) production and nuclear factor-kappaB (NF-kappaB) activation in human umbilical vein endothelial cells (HUVECs).	rebamipide	72-82	C-X-C motif chemokine ligand 8	Homo sapiens	134-147
20607584-1	2010	OBJECTIVE: This study was designed to identify the inhibitory effect of rebamipide on tumor necrosis factor-alpha (TNF-alpha)-induced interleukin-8 (IL-8) production and nuclear factor-kappaB (NF-kappaB) activation in human umbilical vein endothelial cells (HUVECs).	rebamipide	72-82	C-X-C motif chemokine ligand 8	Homo sapiens	149-153
20607584-2	2010	METHODS: After stimulation with TNF-alpha, HUVECs were treated with rebamipide in a dose-dependent manner.	rebamipide	68-78	tumor necrosis factor	Homo sapiens	32-41
20607584-6	2010	RESULTS: We found that rebamipide decreased the expression of IL-8 in the dose-dependent manner under the treatment with TNF-alpha 10 ng/ml.	rebamipide	23-33	C-X-C motif chemokine ligand 8	Homo sapiens	62-66
20607584-6	2010	RESULTS: We found that rebamipide decreased the expression of IL-8 in the dose-dependent manner under the treatment with TNF-alpha 10 ng/ml.	rebamipide	23-33	tumor necrosis factor	Homo sapiens	121-130
20607584-7	2010	TNF-alpha-induced degradation of IkappaB-alpha at 15 min was maximally observed and rebamipide (2 mM) inhibited TNF-alpha-induced phosphorylation of IkappaB-alpha in the cytoplasm of endothelial cells by western blot analysis.	rebamipide	84-94	tumor necrosis factor	Homo sapiens	0-9
20607584-7	2010	TNF-alpha-induced degradation of IkappaB-alpha at 15 min was maximally observed and rebamipide (2 mM) inhibited TNF-alpha-induced phosphorylation of IkappaB-alpha in the cytoplasm of endothelial cells by western blot analysis.	rebamipide	84-94	tumor necrosis factor	Homo sapiens	112-121
20607584-7	2010	TNF-alpha-induced degradation of IkappaB-alpha at 15 min was maximally observed and rebamipide (2 mM) inhibited TNF-alpha-induced phosphorylation of IkappaB-alpha in the cytoplasm of endothelial cells by western blot analysis.	rebamipide	84-94	NFKB inhibitor alpha	Homo sapiens	149-162
20607584-8	2010	Rebamipide also suppressed TNF-alpha-stimulated NF-kappaB p65 nuclear translocation.	rebamipide	0-10	tumor necrosis factor	Homo sapiens	27-36
20607584-8	2010	Rebamipide also suppressed TNF-alpha-stimulated NF-kappaB p65 nuclear translocation.	rebamipide	0-10	nuclear factor kappa B subunit 1	Homo sapiens	48-57
20607584-9	2010	CONCLUSION: Rebamipide suppresses TNF-alpha-induced IL-8 production through (1) inhibition of IkappaB-alpha phosphorylation in the cytoplasm and (2) blockage of NF-kappaB p65 protein transport into the nucleus.	rebamipide	12-22	tumor necrosis factor	Homo sapiens	34-43
20607584-9	2010	CONCLUSION: Rebamipide suppresses TNF-alpha-induced IL-8 production through (1) inhibition of IkappaB-alpha phosphorylation in the cytoplasm and (2) blockage of NF-kappaB p65 protein transport into the nucleus.	rebamipide	12-22	C-X-C motif chemokine ligand 8	Homo sapiens	52-56
20607584-9	2010	CONCLUSION: Rebamipide suppresses TNF-alpha-induced IL-8 production through (1) inhibition of IkappaB-alpha phosphorylation in the cytoplasm and (2) blockage of NF-kappaB p65 protein transport into the nucleus.	rebamipide	12-22	NFKB inhibitor alpha	Homo sapiens	94-107
20607584-9	2010	CONCLUSION: Rebamipide suppresses TNF-alpha-induced IL-8 production through (1) inhibition of IkappaB-alpha phosphorylation in the cytoplasm and (2) blockage of NF-kappaB p65 protein transport into the nucleus.	rebamipide	12-22	RELA proto-oncogene, NF-kB subunit	Homo sapiens	161-174
20607584-10	2010	We suggest that the anti-inflammatory effect of rebamipide is related to the down-regulation of IL-8 expression that is important in endothelial inflammation.	rebamipide	48-58	C-X-C motif chemokine ligand 8	Homo sapiens	96-100
20625243-4	2010	In this study, we showed that rebamipide significantly suppressed the expression of both PLD1 and PLD2 at a transcriptional level in AGS and MKN-1 gastric cancer cells.	rebamipide	30-40	phospholipase D1	Homo sapiens	89-93
20625243-4	2010	In this study, we showed that rebamipide significantly suppressed the expression of both PLD1 and PLD2 at a transcriptional level in AGS and MKN-1 gastric cancer cells.	rebamipide	30-40	phospholipase D2	Homo sapiens	98-102
20625243-5	2010	Downregulation of PLD expression by rebamipide inhibited its enzymatic activity.	rebamipide	36-46	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	18-21
20625243-6	2010	In addition, rebamipide inhibited the transactivation of nuclear factor kappa B (NFkappaB), which increased PLD1 expression.	rebamipide	13-23	nuclear factor kappa B subunit 1	Homo sapiens	57-79
20625243-6	2010	In addition, rebamipide inhibited the transactivation of nuclear factor kappa B (NFkappaB), which increased PLD1 expression.	rebamipide	13-23	nuclear factor kappa B subunit 1	Homo sapiens	81-89
20625243-6	2010	In addition, rebamipide inhibited the transactivation of nuclear factor kappa B (NFkappaB), which increased PLD1 expression.	rebamipide	13-23	phospholipase D1	Homo sapiens	108-112
20625243-8	2010	In conclusion, rebamipide-induced downregulation of PLD may contribute to the inhibition of inflammation and proliferation in gastric cancer.	rebamipide	15-25	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	52-55
18787063-7	2008	Administration of rebamipide, a gastroprotective drug that acts as an oxygen-derived free radical scavenger, significantly decreased LPO and nitrotyrosine as well as the nitration of ERK by peroxynitrite in PHT gastric mucosa, therefore normalizing ERK activation and restoring the gastric mucosal healing response to ethanol injury.	rebamipide	18-28	Eph receptor B1	Rattus norvegicus	183-186
19826186-7	2009	Rebamipide dose-dependently suppressed the ulcerogenic response to alendronate, with a concomitant reversal of the increased vascular permeability, MPO activity and lipid peroxidation as well as the reduced SOD activity and GSH content.	rebamipide	0-10	myeloperoxidase	Rattus norvegicus	148-151
18975081-0	2009	Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test.	rebamipide	0-10	gastrin	Homo sapiens	107-114
18975081-6	2009	Total gastric mucin output was significantly increased by 53% by rebamipide administration from 3.2 +/- 1.2 mg hexose/10 min to 4.9 +/- 2.2 mg hexose/10 min (P &lt; 0.01).	rebamipide	65-75	LOC100508689	Homo sapiens	14-19
18975081-7	2009	Further analysis by ion-exchange chromatography revealed that rebamipide administration induced a specific increase in acidic mucin rich in sialic acid.	rebamipide	62-72	LOC100508689	Homo sapiens	126-131
18781650-3	2009	We synthesized several peptide derivatives of rebamipide and examined their inhibitory effect on the uptake of [(3)H]Gly-Sar by PEPT1-expressing HeLa cells.	rebamipide	46-56	solute carrier family 15 member 1	Homo sapiens	128-133
19483297-0	2009	[Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide].	rebamipide	1-11	toll like receptor 4	Homo sapiens	36-40
19483297-0	2009	[Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide].	rebamipide	1-11	tumor necrosis factor	Homo sapiens	45-54
19483297-1	2009	OBJECTIVE: To determine the effect of rebamipide on the expression of Toll-like recepter 4 (TLR4) and TNF-alpha release in pulmonary epithelial cell line A549.	rebamipide	38-48	toll like receptor 4	Homo sapiens	70-90
19483297-1	2009	OBJECTIVE: To determine the effect of rebamipide on the expression of Toll-like recepter 4 (TLR4) and TNF-alpha release in pulmonary epithelial cell line A549.	rebamipide	38-48	toll like receptor 4	Homo sapiens	92-96
19483297-1	2009	OBJECTIVE: To determine the effect of rebamipide on the expression of Toll-like recepter 4 (TLR4) and TNF-alpha release in pulmonary epithelial cell line A549.	rebamipide	38-48	tumor necrosis factor	Homo sapiens	102-111
18774778-8	2008	This is the first study to demonstrate that claudin-3 is involved in the barrier function of gastric epithelial cells and that rebamipide abolishes the H2O2-induced decrease in claudin-3 protein.	rebamipide	127-137	claudin 3	Homo sapiens	177-186
18787063-7	2008	Administration of rebamipide, a gastroprotective drug that acts as an oxygen-derived free radical scavenger, significantly decreased LPO and nitrotyrosine as well as the nitration of ERK by peroxynitrite in PHT gastric mucosa, therefore normalizing ERK activation and restoring the gastric mucosal healing response to ethanol injury.	rebamipide	18-28	Eph receptor B1	Rattus norvegicus	249-252
17171453-8	2007	Inactivation of ERK2 by PD98059 partly attenuated rebamipide-induced p21 expression.	rebamipide	50-60	mitogen-activated protein kinase 1	Homo sapiens	16-20
18360096-8	2008	Rebamipide effectively prevented aspirin-induced permeability changes and disruption of ZO-1 distribution.	rebamipide	0-10	tight junction protein 1	Rattus norvegicus	88-92
18240266-8	2008	Rebamipide treatment suppressed the activation of CD4+ T cells and Th1 cytokines (interleukin-2, interferon-gamma) associated with impaired NF-kappaB activity.	rebamipide	0-10	negative elongation factor complex member C/D, Th1l	Mus musculus	67-70
18240266-8	2008	Rebamipide treatment suppressed the activation of CD4+ T cells and Th1 cytokines (interleukin-2, interferon-gamma) associated with impaired NF-kappaB activity.	rebamipide	0-10	interleukin 2	Mus musculus	82-95
18240266-8	2008	Rebamipide treatment suppressed the activation of CD4+ T cells and Th1 cytokines (interleukin-2, interferon-gamma) associated with impaired NF-kappaB activity.	rebamipide	0-10	interferon gamma	Mus musculus	97-113
17936043-0	2008	Rebamipide, anti-gastric ulcer drug, up-regulates the induction of iNOS in proinflammatory cytokine-stimulated hepatocytes.	rebamipide	0-10	nitric oxide synthase 2	Rattus norvegicus	67-71
17936043-3	2008	However, it remains unknown whether rebamipide is involved in the regulation of iNOS gene expression under pathological conditions.	rebamipide	36-46	nitric oxide synthase 2	Rattus norvegicus	80-84
17936043-4	2008	We examined whether rebamipide influences the induction of iNOS in hepatocytes exposed to pro-inflammatory cytokine.	rebamipide	20-30	nitric oxide synthase 2	Rattus norvegicus	59-63
17936043-6	2008	Pretreatment of cells with rebamipide resulted in up-regulation of iNOS induction by IL-1beta, followed by increased NO production.	rebamipide	27-37	nitric oxide synthase 2	Rattus norvegicus	67-71
17936043-6	2008	Pretreatment of cells with rebamipide resulted in up-regulation of iNOS induction by IL-1beta, followed by increased NO production.	rebamipide	27-37	interleukin 1 beta	Rattus norvegicus	85-93
17936043-7	2008	Rebamipide enhanced the degradation of IkappaBalpha and the activation of NF-kappaB.	rebamipide	0-10	NFKB inhibitor alpha	Rattus norvegicus	39-51
17936043-8	2008	Further, rebamipide super-induced the up-regulation of type I IL-1 receptor (IL-1RI), which is essential for iNOS induction in addition to the IkappaB/NF-kappaB pathway.	rebamipide	9-19	nitric oxide synthase 2	Rattus norvegicus	109-113
17936043-9	2008	Transfection experiments revealed that rebamipide increased the transactivation of iNOS promoter and the stability of iNOS mRNA.	rebamipide	39-49	nitric oxide synthase 2	Rattus norvegicus	83-87
17936043-9	2008	Transfection experiments revealed that rebamipide increased the transactivation of iNOS promoter and the stability of iNOS mRNA.	rebamipide	39-49	nitric oxide synthase 2	Rattus norvegicus	118-122
17936043-10	2008	In the latter, rebamipide increased the antisense-transcript corresponding to the 3"-UTR of iNOS mRNA, which stabilizes iNOS mRNA by interacting with the 3"-UTR and RNA-binding proteins.	rebamipide	15-25	nitric oxide synthase 2	Rattus norvegicus	92-96
17936043-10	2008	In the latter, rebamipide increased the antisense-transcript corresponding to the 3"-UTR of iNOS mRNA, which stabilizes iNOS mRNA by interacting with the 3"-UTR and RNA-binding proteins.	rebamipide	15-25	nitric oxide synthase 2	Rattus norvegicus	120-124
17936043-11	2008	These findings demonstrate that rebamipide up-regulates iNOS by iNOS promoter activation through NF-kappaB, and by its mRNA stabilization presumably through the super-induction of IL-1RI and antisense-transcript.	rebamipide	32-42	nitric oxide synthase 2	Rattus norvegicus	56-60
17936043-11	2008	These findings demonstrate that rebamipide up-regulates iNOS by iNOS promoter activation through NF-kappaB, and by its mRNA stabilization presumably through the super-induction of IL-1RI and antisense-transcript.	rebamipide	32-42	nitric oxide synthase 2	Rattus norvegicus	64-68
17943251-8	2007	Rebamipide, given twice daily for 7 days, significantly promoted the delayed ulcer healing caused by alendronate, with the concomitant recovery of bFGF expression.	rebamipide	0-10	fibroblast growth factor 2	Rattus norvegicus	147-151
17607548-1	2007	OBJECTIVE AND DESIGN: Since rebamipide is effective for the treatment of ulcerative colitis (UC), we examined the involvement of hepatocyte growth factor (HGF) in the action of rebamipide.	rebamipide	177-187	hepatocyte growth factor	Mus musculus	129-153
17607548-1	2007	OBJECTIVE AND DESIGN: Since rebamipide is effective for the treatment of ulcerative colitis (UC), we examined the involvement of hepatocyte growth factor (HGF) in the action of rebamipide.	rebamipide	177-187	hepatocyte growth factor	Mus musculus	155-158
17607548-9	2007	Expression of HGF was greatly increased in rebamipide-treated mice.	rebamipide	43-53	hepatocyte growth factor	Mus musculus	14-17
17607548-11	2007	CONCLUSIONS: Rectal administration of rebamipide is effective for DSS-induced colitis in association with induction of HGF.	rebamipide	38-48	hepatocyte growth factor	Mus musculus	119-122
17171453-3	2007	We examined whether rebamipide affects human gastric cancer cell proliferation and activation of Smad signaling pathway.	rebamipide	20-30	SMAD family member 4	Homo sapiens	97-101
17171453-6	2007	Rebamipide treatment inhibited AGS cell proliferation and increased p21, Smad2/3 phosphorylation, and Smad2/3-Smad4 complex formation.	rebamipide	0-10	H3 histone pseudogene 16	Homo sapiens	68-71
17171453-6	2007	Rebamipide treatment inhibited AGS cell proliferation and increased p21, Smad2/3 phosphorylation, and Smad2/3-Smad4 complex formation.	rebamipide	0-10	SMAD family member 2	Homo sapiens	73-80
17171453-6	2007	Rebamipide treatment inhibited AGS cell proliferation and increased p21, Smad2/3 phosphorylation, and Smad2/3-Smad4 complex formation.	rebamipide	0-10	SMAD family member 2	Homo sapiens	102-109
17171453-6	2007	Rebamipide treatment inhibited AGS cell proliferation and increased p21, Smad2/3 phosphorylation, and Smad2/3-Smad4 complex formation.	rebamipide	0-10	SMAD family member 4	Homo sapiens	110-115
17171453-7	2007	Rebamipide induced phosphorylation of ERK2 but not JNK or p38.	rebamipide	0-10	mitogen-activated protein kinase 1	Homo sapiens	38-42
17171453-8	2007	Inactivation of ERK2 by PD98059 partly attenuated rebamipide-induced p21 expression.	rebamipide	50-60	H3 histone pseudogene 16	Homo sapiens	69-72
17171453-9	2007	These data demonstrate that rebamipide activates Smad signaling pathway and suppresses human gastric cancer cell growth.	rebamipide	28-38	SMAD family member 4	Homo sapiens	49-53
17171453-10	2007	Inactivation of ERK2 partly inhibited rebamipide-induced p21 expression, indicating a crosstalk between ERK and Smad signaling pathways.	rebamipide	38-48	mitogen-activated protein kinase 1	Homo sapiens	16-20
17171453-10	2007	Inactivation of ERK2 partly inhibited rebamipide-induced p21 expression, indicating a crosstalk between ERK and Smad signaling pathways.	rebamipide	38-48	H3 histone pseudogene 16	Homo sapiens	57-60
17171453-10	2007	Inactivation of ERK2 partly inhibited rebamipide-induced p21 expression, indicating a crosstalk between ERK and Smad signaling pathways.	rebamipide	38-48	mitogen-activated protein kinase 1	Homo sapiens	16-19
17171453-10	2007	Inactivation of ERK2 partly inhibited rebamipide-induced p21 expression, indicating a crosstalk between ERK and Smad signaling pathways.	rebamipide	38-48	SMAD family member 4	Homo sapiens	112-116
17186389-3	2007	Mice treated with rebamipide presented a reinforcement of the distal colonic epithelial barrier, an increase of mesenteric lymph node cells proliferation, and of IFNgamma and IL-12 secretion.	rebamipide	18-28	interferon gamma	Mus musculus	162-170
17186389-4	2007	These results indicate that in IL-10-/- mice with mild colitis, rectally administered rebamipide reinforces the distal colonic barrier and has a slight Th1 immuno-stimulatory effect on mesenteric lymph node cells.	rebamipide	86-96	interleukin 10	Mus musculus	31-36
17186389-4	2007	These results indicate that in IL-10-/- mice with mild colitis, rectally administered rebamipide reinforces the distal colonic barrier and has a slight Th1 immuno-stimulatory effect on mesenteric lymph node cells.	rebamipide	86-96	negative elongation factor complex member C/D, Th1l	Mus musculus	152-155
15833277-12	2005	Treatment of DPI or rebamipide and transfection of AS ODNs for NADPH oxidase subunits suppressed cerulein-induced NF-kappaB activation and IL-6 expression compared to S ODNs.	rebamipide	20-30	interleukin 6	Rattus norvegicus	139-143
16039106-0	2006	The inhibitory effects of rebamipide on cigarette smoke-induced airway mucin production.	rebamipide	26-36	solute carrier family 13 member 2	Rattus norvegicus	71-76
16039106-4	2006	Rebamipide (2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid, OPC-12759) directly inhibits the production of superoxide (O2-) and inhibits proinflammatory cytokines (such as TNFalpha and IL-8).	rebamipide	0-10	tumor necrosis factor	Rattus norvegicus	191-199
16039106-4	2006	Rebamipide (2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid, OPC-12759) directly inhibits the production of superoxide (O2-) and inhibits proinflammatory cytokines (such as TNFalpha and IL-8).	rebamipide	12-77	tumor necrosis factor	Rattus norvegicus	191-199
16039106-4	2006	Rebamipide (2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid, OPC-12759) directly inhibits the production of superoxide (O2-) and inhibits proinflammatory cytokines (such as TNFalpha and IL-8).	rebamipide	79-88	tumor necrosis factor	Rattus norvegicus	191-199
16039106-5	2006	In the present study, we aimed to analyze the inhibitory effects of rebamipide on TNFalpha and EGFR activation after cigarette smoke treatment in vitro and in vivo.	rebamipide	68-78	tumor necrosis factor	Rattus norvegicus	82-90
16039106-5	2006	In the present study, we aimed to analyze the inhibitory effects of rebamipide on TNFalpha and EGFR activation after cigarette smoke treatment in vitro and in vivo.	rebamipide	68-78	epidermal growth factor receptor	Rattus norvegicus	95-99
16039106-8	2006	These effects were inhibited dose-dependently by pretreatment with rebamipide (MUC5AC protein levels were inhibited from 44% to 17%, P&lt;0.05).	rebamipide	67-77	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	79-85
16039106-10	2006	Moreover, the pretreatment of rats with rebamipide inhibited goblet cell metaplasia and TNFalpha secretion, dose-dependently (from 2270+/-158 to 1377+/-112 pg/ml, P&lt;0.05).	rebamipide	40-50	tumor necrosis factor	Rattus norvegicus	88-96
16039106-12	2006	Moreover, rebamipide was found to prevent this cigarette smoke-induced TNFalpha release, and mucin production.	rebamipide	10-20	tumor necrosis factor	Rattus norvegicus	71-79
16039106-12	2006	Moreover, rebamipide was found to prevent this cigarette smoke-induced TNFalpha release, and mucin production.	rebamipide	10-20	solute carrier family 13 member 2	Rattus norvegicus	93-98
16184411-7	2005	Among the 158 genes that were induced by indomethacin at least 2.0-fold, four genes that were down-regulated by rebamipide at least 2.0-fold are listed: growth arrest and DNA-damage-inducible 45 alpha (GADD 45 alpha), golgi SNAP receptor complex member 1, iodothyronine deiodinases, and transcription factor 8.	rebamipide	112-122	growth arrest and DNA-damage-inducible, alpha	Rattus norvegicus	153-200
16184411-7	2005	Among the 158 genes that were induced by indomethacin at least 2.0-fold, four genes that were down-regulated by rebamipide at least 2.0-fold are listed: growth arrest and DNA-damage-inducible 45 alpha (GADD 45 alpha), golgi SNAP receptor complex member 1, iodothyronine deiodinases, and transcription factor 8.	rebamipide	112-122	growth arrest and DNA-damage-inducible, alpha	Rattus norvegicus	202-215
16184411-7	2005	Among the 158 genes that were induced by indomethacin at least 2.0-fold, four genes that were down-regulated by rebamipide at least 2.0-fold are listed: growth arrest and DNA-damage-inducible 45 alpha (GADD 45 alpha), golgi SNAP receptor complex member 1, iodothyronine deiodinases, and transcription factor 8.	rebamipide	112-122	golgi SNAP receptor complex member 1	Rattus norvegicus	218-309
16184411-8	2005	Real time-PCR confirmed GADD 45 alpha expression and its inhibition by rebamipide.	rebamipide	71-81	growth arrest and DNA-damage-inducible, alpha	Rattus norvegicus	24-37
16184422-7	2005	Rebamipide significantly inhibited WIR-induced increase in gastric MPO activity at 8 hr after WIR.	rebamipide	0-10	myeloperoxidase	Rattus norvegicus	67-70
16184423-0	2005	Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice.	rebamipide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	53-69
16184423-1	2005	Rebamipide is an antiulcer drug capable of various actions including the induction of cyclooxygenase-2 (COX-2).	rebamipide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	86-102
16184423-1	2005	Rebamipide is an antiulcer drug capable of various actions including the induction of cyclooxygenase-2 (COX-2).	rebamipide	0-10	prostaglandin-endoperoxide synthase 2	Mus musculus	104-109
16184423-6	2005	In wild-type mice, rebamipide accelerated ulcer healing and increased COX-2 mRNA expression.	rebamipide	19-29	prostaglandin-endoperoxide synthase 2	Mus musculus	70-75
16184423-7	2005	In COX-2-deficient mice, rebamipide prevented delayed ulcer healing and reversed the inhibition in angiogenesis and bFGF mRNA expression.	rebamipide	25-35	prostaglandin-endoperoxide synthase 2	Mus musculus	3-8
16184423-7	2005	In COX-2-deficient mice, rebamipide prevented delayed ulcer healing and reversed the inhibition in angiogenesis and bFGF mRNA expression.	rebamipide	25-35	fibroblast growth factor 2	Mus musculus	116-120
16184423-8	2005	The effect of rebamipide on the enhancement of ulcer healing, angiogenesis, and induction of bFGF expression was more prominent in wild-type mice than in COX-2-deficient mice.	rebamipide	14-24	fibroblast growth factor 2	Mus musculus	93-97
16184423-8	2005	The effect of rebamipide on the enhancement of ulcer healing, angiogenesis, and induction of bFGF expression was more prominent in wild-type mice than in COX-2-deficient mice.	rebamipide	14-24	prostaglandin-endoperoxide synthase 2	Mus musculus	154-159
16184423-9	2005	In conclusion, rebamipide may accelerate gastric ulcer healing through both COX-2-dependent and COX-2-independent mechanisms.	rebamipide	15-25	prostaglandin-endoperoxide synthase 2	Mus musculus	76-81
16184423-9	2005	In conclusion, rebamipide may accelerate gastric ulcer healing through both COX-2-dependent and COX-2-independent mechanisms.	rebamipide	15-25	prostaglandin-endoperoxide synthase 2	Mus musculus	96-101
16184426-0	2005	Rebamipide reduces indomethacin-induced gastric injury in mice via down-regulation of ICAM-1 expression.	rebamipide	0-10	intercellular adhesion molecule 1	Mus musculus	86-92
16184426-7	2005	Furthermore, rebamipide pre-treatment notably decreased intercellular adhesion molecule-1 (ICAM-1) expression that was up-regulated in gastric tissue treated with indomethacin.	rebamipide	13-23	intercellular adhesion molecule 1	Mus musculus	56-89
16184426-7	2005	Furthermore, rebamipide pre-treatment notably decreased intercellular adhesion molecule-1 (ICAM-1) expression that was up-regulated in gastric tissue treated with indomethacin.	rebamipide	13-23	intercellular adhesion molecule 1	Mus musculus	91-97
16184426-8	2005	Therefore, rebamipide may reduce indomethacin-induced gastric mucosal injuries through its antioxidant effect, which inhibits the neutrophil activation step following up-regulation of ICAM-1 expression on endothelial cells.	rebamipide	11-21	intercellular adhesion molecule 1	Mus musculus	184-190
15993841-0	2005	Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B.	rebamipide	0-10	aurora kinase B	Homo sapiens	68-76
16170898-14	2005	Rebamipide pretreatment reduced both COX-2 expression and IR injury.	rebamipide	0-10	cytochrome c oxidase II, mitochondrial	Mus musculus	37-42
16462041-4	2006	The absorption of rebamipide from rabbit rectum was more markedly improved by suppositories containing C12 than C10 suppositories.	rebamipide	18-28	chromosome 12 open reading frame 57	Homo sapiens	112-115
16416182-1	2005	Rebamipide has a broad spectrum of pharmacological actions that include suppression of neutrophil functions and stimulation of mucosal epithelial cell regeneration by increasing the expression of epithelial growth factor (EGF) and the EGF receptor.	rebamipide	0-10	epidermal growth factor	Homo sapiens	196-220
16416182-1	2005	Rebamipide has a broad spectrum of pharmacological actions that include suppression of neutrophil functions and stimulation of mucosal epithelial cell regeneration by increasing the expression of epithelial growth factor (EGF) and the EGF receptor.	rebamipide	0-10	epidermal growth factor	Homo sapiens	222-225
16416182-1	2005	Rebamipide has a broad spectrum of pharmacological actions that include suppression of neutrophil functions and stimulation of mucosal epithelial cell regeneration by increasing the expression of epithelial growth factor (EGF) and the EGF receptor.	rebamipide	0-10	epidermal growth factor receptor	Homo sapiens	235-247
16184427-10	2005	Rebamipide suppressed the decrease in GSHpx activity on day 60.	rebamipide	0-10	glutathione peroxidase 1	Rattus norvegicus	38-43
16184428-6	2005	Lesion index (LI), thiobarbituric acid-reactive substances (TBA-RS), myeloperoxidase (MPO) activity, mRNA and protein of tumor necrosis factor (TNF)-alpha and cytokine-induced neutrophil chemoattractant (CINC)-1 in the esophageal mucosa were markedly increased; pretreatment with rebamipide, however, significantly reduced both macroscopic and microscopic injuries and increases in inflammatory mediators.	rebamipide	280-290	C-X-C motif chemokine ligand 1	Rattus norvegicus	159-211
15104358-0	2004	Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?	rebamipide	0-10	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	66-70
15556137-3	2004	CCK-8S and rebamipide inhibited [125I]BH-CCK-8S binding to rat pancreatic acinar cell membranes with IC50 values of 3.13 nM and 37.7 microM, respectively.	rebamipide	11-21	cholecystokinin	Rattus norvegicus	41-44
15556137-6	2004	In addition, rebamipide was shown to inhibit high concentrations of CCK-8S-induced biphasic increases in [Ca2+]i, suggesting that rebamipide might be a partial agonist at cholecystokinin CCK1 receptors.	rebamipide	13-23	cholecystokinin	Rattus norvegicus	68-71
15556137-6	2004	In addition, rebamipide was shown to inhibit high concentrations of CCK-8S-induced biphasic increases in [Ca2+]i, suggesting that rebamipide might be a partial agonist at cholecystokinin CCK1 receptors.	rebamipide	130-140	cholecystokinin	Rattus norvegicus	68-71
15556137-7	2004	Although rebamipide induced [Ca2+]i oscillations by activating the cholecystokinin CCK1 receptors, rebamipide did not cause amylase release and only inhibited CCK-stimulated amylase release reversibly and dose-dependently.	rebamipide	9-19	cholecystokinin	Rattus norvegicus	83-86
15556137-9	2004	These data indicate that rebamipide functions as a partial agonist for Ca2+ -mobilizing action, and it is also an antagonist for the amylase-releasing action of CCK.	rebamipide	25-35	cholecystokinin	Rattus norvegicus	161-164
14738594-7	2003	Secondly, we studied the inhibition of CYP2A6 with clinically used drugs of quinoline compounds, such as norfloxacin as an antibacterial agent, quinidine as an antiarrhythmic agent, quinine and chloroquine as antimalaria agents and rebamipide as an anti-ulcer agent.	rebamipide	232-242	cytochrome P450 2A13	Bos taurus	39-45
12661076-3	2003	Comparing C12 with sodium caprate (C10), used in drug products marketed, 100 micromol C10 was needed to exert the similar absorption-enhancement of rebamipide, a poorly absorbable antiulcer drug, to that by 10 micromol C12, and 100 micromol C10 was obviously more toxic to the mucosa than 10 micromol C12.	rebamipide	148-158	chromosome 12 open reading frame 57	Homo sapiens	86-89
12925143-0	2003	Rebamipide binds to iNOS-positive cells in acetic acid-treated but not in ethanol-treated rat gastric mucosa.	rebamipide	0-10	nitric oxide synthase 2	Rattus norvegicus	20-24
12925143-10	2003	Combination of autoradiography and immunohistochemistry has revealed that iNOS-immunoreactive cells had the strong binding of rebamipide in the acetic acid-treated group.	rebamipide	126-136	nitric oxide synthase 2	Rattus norvegicus	74-78
12925143-13	2003	CONCLUSIONS: Autoradiography has made it clear that rebamipide binds to iNOS-positive cells in the gastric mucosa 7 days after acetic acid-treatment.	rebamipide	52-62	nitric oxide synthase 2	Rattus norvegicus	72-76
12925145-12	2003	Long-term administration of rebamipide reduced the level of HIF-1alpha.	rebamipide	28-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	60-70
12925147-4	2003	We have tested the hypothesis that the ulcer healing mechanism stimulated by rebamipide is linked physiologically to the gastric midkine-RPTP-beta system.	rebamipide	77-87	midkine	Rattus norvegicus	129-136
12925147-4	2003	We have tested the hypothesis that the ulcer healing mechanism stimulated by rebamipide is linked physiologically to the gastric midkine-RPTP-beta system.	rebamipide	77-87	protein tyrosine phosphatase, receptor type Z1	Rattus norvegicus	137-146
12925147-7	2003	The effects of rebamipide on midkine and RPTP-beta expression in rat stomach and the gastric epithelial cell line RGM1 were evaluated by RT-PCR and Northern blot analyses.	rebamipide	15-25	midkine	Rattus norvegicus	29-36
12925147-7	2003	The effects of rebamipide on midkine and RPTP-beta expression in rat stomach and the gastric epithelial cell line RGM1 were evaluated by RT-PCR and Northern blot analyses.	rebamipide	15-25	protein tyrosine phosphatase, receptor type Z1	Rattus norvegicus	41-50
12925147-9	2003	Rebamipide stimulated both midkine and RPTP-beta expression in rat stomach and RGM1 cells.	rebamipide	0-10	midkine	Rattus norvegicus	27-34
12925147-9	2003	Rebamipide stimulated both midkine and RPTP-beta expression in rat stomach and RGM1 cells.	rebamipide	0-10	protein tyrosine phosphatase, receptor type Z1	Rattus norvegicus	39-48
12925150-15	2003	Rebamipide induced PGE2 and HGF.	rebamipide	0-10	hepatocyte growth factor	Homo sapiens	28-31
12925150-16	2003	CONCLUSION: DEX inhibits restitution via HGF depletion, and rebamipide reverses the inhibited restitution by HGF induction.	rebamipide	60-70	hepatocyte growth factor	Homo sapiens	109-112
12925151-8	2003	The effect of rebamipide was evaluated by measuring TER.	rebamipide	14-24	trans-2,3-enoyl-CoA reductase	Rattus norvegicus	52-55
12925151-15	2003	Rebamipide suppressed an indometacin-induced increase in gastric epithelial permeability by increasing PGE2 levels in a COX-2 dependent manner.	rebamipide	0-10	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	120-125
12925153-4	2003	They randomly received either rebamipide (OA-R) or placebo (OA-P) for 16 weeks: combined with the OA based therapy, and subsequently for another 8 weeks.	rebamipide	30-40	Ocular albinism, autosomal recessive	Homo sapiens	42-46
12661076-3	2003	Comparing C12 with sodium caprate (C10), used in drug products marketed, 100 micromol C10 was needed to exert the similar absorption-enhancement of rebamipide, a poorly absorbable antiulcer drug, to that by 10 micromol C12, and 100 micromol C10 was obviously more toxic to the mucosa than 10 micromol C12.	rebamipide	148-158	chromosome 12 open reading frame 57	Homo sapiens	86-89
12678329-3	2003	Since prostaglandins are inducers of hepatocyte growth factor (HGF), we examined the effect of rebamipide on the expression of HGF, c-met, cyclooxygenase-2 (Cox-2) and subtype of the prostaglandin E2 receptor (EP2) in acetic acid-induced gastric ulcer, a model of human ulcer.	rebamipide	95-105	hepatocyte growth factor	Homo sapiens	127-130
12678329-3	2003	Since prostaglandins are inducers of hepatocyte growth factor (HGF), we examined the effect of rebamipide on the expression of HGF, c-met, cyclooxygenase-2 (Cox-2) and subtype of the prostaglandin E2 receptor (EP2) in acetic acid-induced gastric ulcer, a model of human ulcer.	rebamipide	95-105	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	132-137
12678329-3	2003	Since prostaglandins are inducers of hepatocyte growth factor (HGF), we examined the effect of rebamipide on the expression of HGF, c-met, cyclooxygenase-2 (Cox-2) and subtype of the prostaglandin E2 receptor (EP2) in acetic acid-induced gastric ulcer, a model of human ulcer.	rebamipide	95-105	prostaglandin-endoperoxide synthase 2	Homo sapiens	139-155
12678329-3	2003	Since prostaglandins are inducers of hepatocyte growth factor (HGF), we examined the effect of rebamipide on the expression of HGF, c-met, cyclooxygenase-2 (Cox-2) and subtype of the prostaglandin E2 receptor (EP2) in acetic acid-induced gastric ulcer, a model of human ulcer.	rebamipide	95-105	prostaglandin-endoperoxide synthase 2	Homo sapiens	157-162
12678329-8	2003	RESULTS: In the rebamipide group, gastric ulcer index was significantly smaller than in the control group at each time-point except at 10 days (P &lt; 0.05, each); up-regulation of HGF, c-met, Cox-2 and EP2 mRNA was also observed.	rebamipide	16-26	hepatocyte growth factor	Rattus norvegicus	181-184
12678329-8	2003	RESULTS: In the rebamipide group, gastric ulcer index was significantly smaller than in the control group at each time-point except at 10 days (P &lt; 0.05, each); up-regulation of HGF, c-met, Cox-2 and EP2 mRNA was also observed.	rebamipide	16-26	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	186-191
12678329-8	2003	RESULTS: In the rebamipide group, gastric ulcer index was significantly smaller than in the control group at each time-point except at 10 days (P &lt; 0.05, each); up-regulation of HGF, c-met, Cox-2 and EP2 mRNA was also observed.	rebamipide	16-26	prostaglandin-endoperoxide synthase 2	Homo sapiens	193-198
12678329-8	2003	RESULTS: In the rebamipide group, gastric ulcer index was significantly smaller than in the control group at each time-point except at 10 days (P &lt; 0.05, each); up-regulation of HGF, c-met, Cox-2 and EP2 mRNA was also observed.	rebamipide	16-26	prostaglandin E receptor 2	Rattus norvegicus	203-206
12678329-10	2003	The PCNA-labelled epithelial cells in the rebamipide group were also greater than in the control group on days 10, 30, 90 and 120 (P &lt; 0.05, each).	rebamipide	42-52	proliferating cell nuclear antigen	Rattus norvegicus	4-8
12678329-11	2003	CONCLUSION: The study suggests that rebamipide has anti-ulcerative effects on gastric mucosal cells via up-regulation of HGF, c-met, Cox-2 and EP2.	rebamipide	36-46	hepatocyte growth factor	Rattus norvegicus	121-124
12678329-11	2003	CONCLUSION: The study suggests that rebamipide has anti-ulcerative effects on gastric mucosal cells via up-regulation of HGF, c-met, Cox-2 and EP2.	rebamipide	36-46	MET proto-oncogene, receptor tyrosine kinase	Rattus norvegicus	126-131
12678329-11	2003	CONCLUSION: The study suggests that rebamipide has anti-ulcerative effects on gastric mucosal cells via up-regulation of HGF, c-met, Cox-2 and EP2.	rebamipide	36-46	prostaglandin-endoperoxide synthase 2	Homo sapiens	133-138
12678329-11	2003	CONCLUSION: The study suggests that rebamipide has anti-ulcerative effects on gastric mucosal cells via up-regulation of HGF, c-met, Cox-2 and EP2.	rebamipide	36-46	prostaglandin E receptor 2	Rattus norvegicus	143-146
11991622-5	2002	Sera from patients treated with rebamipide showed a significant decrease in gastrin (276.3 +/- 58.3 pg/ml vs 173.0 +/- 34.2 pg/ml; P &lt; 0.05), whereas no change was observed in the control group.	rebamipide	32-42	gastrin	Homo sapiens	76-83
14506330-0	2003	Preoperative administration of rebamipide significantly lowers body temperature and circulating interleukin-6 in gastric cancer patients after gastrectomy.	rebamipide	31-41	interleukin 6	Homo sapiens	96-109
14506330-14	2003	CONCLUSION: Preoperative administration of rebamipide significantly decreased postoperative body temperatures and circulating IL-6 in gastric cancer patients after gastrectomy to levels similar to those of patients with LADG.	rebamipide	43-53	interleukin 6	Homo sapiens	126-130
12162853-0	2002	Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver.	rebamipide	52-62	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	26-30
12162853-2	2002	The metabolism of rebamipide, a gastroprotective agent, was investigated using human liver microsomes and cDNA-expressed human cytochrome P450 systems.	rebamipide	18-28	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	138-142
12162853-9	2002	Furthermore, the metabolism of rebamipide in human liver microsomes was compatible with that in a human cDNA-expressed CYP3A4 system, but not for other human P450 expression systems.	rebamipide	31-41	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	119-125
12162853-10	2002	It is therefore suggested that the hydroxylation of rebamipide only involves CYP3A4.	rebamipide	52-62	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	77-83
12162853-14	2002	It is therefore considered that drug interactions with cytochrome P450 enzymes are not involved in either the metabolism of rebamipide or the metabolism of other drugs concomitantly administered with rebamipide.	rebamipide	124-134	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	66-70
12162853-14	2002	It is therefore considered that drug interactions with cytochrome P450 enzymes are not involved in either the metabolism of rebamipide or the metabolism of other drugs concomitantly administered with rebamipide.	rebamipide	200-210	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	66-70
11991622-6	2002	These suggest that long-term rebamipide treatment improved histologic gastritis and decreased serum gastrin levels in H. pylori-associated gastritis.	rebamipide	29-39	gastrin	Homo sapiens	100-107
11855542-6	2002	The mucosal production of RANTES, interleukin-8, and TNF-alpha showed a significant decrease after eradication in patients with rebamipide after-treatment.	rebamipide	128-138	C-C motif chemokine ligand 5	Homo sapiens	26-32
11855542-6	2002	The mucosal production of RANTES, interleukin-8, and TNF-alpha showed a significant decrease after eradication in patients with rebamipide after-treatment.	rebamipide	128-138	C-X-C motif chemokine ligand 8	Homo sapiens	34-47
11855542-6	2002	The mucosal production of RANTES, interleukin-8, and TNF-alpha showed a significant decrease after eradication in patients with rebamipide after-treatment.	rebamipide	128-138	tumor necrosis factor	Homo sapiens	53-62
11259567-0	2001	Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils.	rebamipide	0-10	formyl peptide receptor 1	Homo sapiens	61-65
11731719-5	2002	Rebamipide suppressed both cell death and a reduction in HSP70 induced by the combined treatment of heat shock and quercetin.	rebamipide	0-10	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	57-62
11731719-9	2002	The protective action of rebamipide appears to be at least partially due to maintenance of the HSP70 level.	rebamipide	25-35	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	95-100
11686837-9	2001	The protection by rebamipide was accompanied by a significant suppression of the increase in both MPO and iNOS activities, and a complete inhibition of the increase in TBA reactants, while SOD + CAT significantly inhibited the increase of MPO activity and TBA reactants, but not iNOS activity.	rebamipide	18-28	myeloperoxidase	Rattus norvegicus	98-101
11686837-9	2001	The protection by rebamipide was accompanied by a significant suppression of the increase in both MPO and iNOS activities, and a complete inhibition of the increase in TBA reactants, while SOD + CAT significantly inhibited the increase of MPO activity and TBA reactants, but not iNOS activity.	rebamipide	18-28	nitric oxide synthase 2	Rattus norvegicus	106-110
11686837-9	2001	The protection by rebamipide was accompanied by a significant suppression of the increase in both MPO and iNOS activities, and a complete inhibition of the increase in TBA reactants, while SOD + CAT significantly inhibited the increase of MPO activity and TBA reactants, but not iNOS activity.	rebamipide	18-28	catalase	Rattus norvegicus	195-198
11686837-9	2001	The protection by rebamipide was accompanied by a significant suppression of the increase in both MPO and iNOS activities, and a complete inhibition of the increase in TBA reactants, while SOD + CAT significantly inhibited the increase of MPO activity and TBA reactants, but not iNOS activity.	rebamipide	18-28	myeloperoxidase	Rattus norvegicus	239-242
11686837-9	2001	The protection by rebamipide was accompanied by a significant suppression of the increase in both MPO and iNOS activities, and a complete inhibition of the increase in TBA reactants, while SOD + CAT significantly inhibited the increase of MPO activity and TBA reactants, but not iNOS activity.	rebamipide	18-28	nitric oxide synthase 2	Rattus norvegicus	279-283
11454909-0	2001	Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells.	rebamipide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	37-50
11454909-4	2001	In this study, we evaluated the effect of rebamipide, an antigastritis and antiulcer agent, on H. pylori-dependent ceramide production and subsequent interleukin-8 expression in Kato III cells.	rebamipide	42-52	C-X-C motif chemokine ligand 8	Homo sapiens	150-163
11454909-5	2001	Rebamipide inhibited ceramide-induced interleukin-8 expression in a dose-dependent manner.	rebamipide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	38-51
11454909-6	2001	Rebamipide decreased the ceramide-induced increase of the interleukin-8 mRNA level as assessed by Northern blotting.	rebamipide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	58-71
11454909-7	2001	Rebamipide suppressed interleukin-8 gene transcription and nuclear factor-kappaB-dependent transcriptional activity as assessed by luciferase assay.	rebamipide	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	22-35
11454909-8	2001	Rebamipide inhibited the ceramide-induced degradation of IkappaB-alpha (a major cytoplasmic inhibitor of nuclear factor-kappaB), further supporting that rebamipide inhibits the activation of nuclear factor-kappaB.	rebamipide	0-10	NFKB inhibitor alpha	Homo sapiens	57-70
11454909-8	2001	Rebamipide inhibited the ceramide-induced degradation of IkappaB-alpha (a major cytoplasmic inhibitor of nuclear factor-kappaB), further supporting that rebamipide inhibits the activation of nuclear factor-kappaB.	rebamipide	153-163	NFKB inhibitor alpha	Homo sapiens	57-70
11394942-2	2001	In the in vitro study, the significant production of superoxide anion that was identified 3 hours after application of 10% whole blood to the rat aortic segments was inhibited by rebamipide (100 and 300 microM) and these results were correlated with the in vitro intercellular adhesion molecule-1 (ICAM-1) expression on the femoral artery.	rebamipide	179-189	intercellular adhesion molecule 1	Rattus norvegicus	263-296
11394942-2	2001	In the in vitro study, the significant production of superoxide anion that was identified 3 hours after application of 10% whole blood to the rat aortic segments was inhibited by rebamipide (100 and 300 microM) and these results were correlated with the in vitro intercellular adhesion molecule-1 (ICAM-1) expression on the femoral artery.	rebamipide	179-189	intercellular adhesion molecule 1	Rattus norvegicus	298-304
11259567-6	2001	Scatchard analysis of [3H]fMLP binding to human neutrophil membrane revealed that rebamipide increased the K(D) value of [3H]fMLP without altering the number of [3H]fMLP binding sites, suggesting that rebamipide has a competitive antagonistic action against the fMLP-receptor.	rebamipide	82-92	formyl peptide receptor 1	Homo sapiens	26-30
11259567-6	2001	Scatchard analysis of [3H]fMLP binding to human neutrophil membrane revealed that rebamipide increased the K(D) value of [3H]fMLP without altering the number of [3H]fMLP binding sites, suggesting that rebamipide has a competitive antagonistic action against the fMLP-receptor.	rebamipide	82-92	formyl peptide receptor 1	Homo sapiens	125-129
11259567-6	2001	Scatchard analysis of [3H]fMLP binding to human neutrophil membrane revealed that rebamipide increased the K(D) value of [3H]fMLP without altering the number of [3H]fMLP binding sites, suggesting that rebamipide has a competitive antagonistic action against the fMLP-receptor.	rebamipide	82-92	formyl peptide receptor 1	Homo sapiens	125-129
11259567-6	2001	Scatchard analysis of [3H]fMLP binding to human neutrophil membrane revealed that rebamipide increased the K(D) value of [3H]fMLP without altering the number of [3H]fMLP binding sites, suggesting that rebamipide has a competitive antagonistic action against the fMLP-receptor.	rebamipide	82-92	formyl peptide receptor 1	Homo sapiens	262-275
11259567-7	2001	The competitive antagonistic action was further confirmed by the finding that rebamipide caused a parallel shift to the right in the dose-response curve of O2 production induced by fMLP.	rebamipide	78-88	formyl peptide receptor 1	Homo sapiens	181-185
11259567-8	2001	These results provide evidence that the competitive inhibitory action of rebamipide on the fMLP-receptor plays a main role in its inhibitory action on fMLP-induced O2 production.	rebamipide	73-83	formyl peptide receptor 1	Homo sapiens	91-104
11259567-8	2001	These results provide evidence that the competitive inhibitory action of rebamipide on the fMLP-receptor plays a main role in its inhibitory action on fMLP-induced O2 production.	rebamipide	73-83	formyl peptide receptor 1	Homo sapiens	91-95
11259567-0	2001	Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils.	rebamipide	0-10	formyl peptide receptor 1	Homo sapiens	111-124
11259567-1	2001	The purpose of the present work was to investigate the mechanism underlying the inhibitory action of rebamipide on superoxide anion (O2) production induced by the chemotactic peptide formyl-methionyl-leucyl-phenylalanine (fMLP) in human neutrophils.	rebamipide	101-111	formyl peptide receptor 1	Homo sapiens	222-226
11259567-3	2001	Rebamipide inhibited PIP(3) production in parallel with the inhibition of fMLP-induced O2 production.	rebamipide	0-10	prolactin induced protein	Homo sapiens	21-24
11259567-3	2001	Rebamipide inhibited PIP(3) production in parallel with the inhibition of fMLP-induced O2 production.	rebamipide	0-10	formyl peptide receptor 1	Homo sapiens	74-78
11046075-0	2000	Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent.	rebamipide	55-65	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	13-29
11046075-10	2000	A COX-2 inhibitor blocked the rebamipide-induced increase in mucosal PGE(2), and mucosal protection induced by rebamipide.	rebamipide	30-40	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	2-7
11046075-10	2000	A COX-2 inhibitor blocked the rebamipide-induced increase in mucosal PGE(2), and mucosal protection induced by rebamipide.	rebamipide	111-121	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	2-7
11046075-7	2000	COX-2 expression was enhanced, whereas COX-1 expression did not change significantly in the gastric mucosa of rats after treatment with rebamipide.	rebamipide	136-146	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	0-5
11046075-11	2000	The results indicate that rebamipide induces COX-2 expression, increases PGE(2) levels, and enhances gastric mucosal defense in a COX-2-dependent manner.	rebamipide	26-36	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	45-50
11046075-11	2000	The results indicate that rebamipide induces COX-2 expression, increases PGE(2) levels, and enhances gastric mucosal defense in a COX-2-dependent manner.	rebamipide	26-36	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	130-135
11046075-12	2000	Thus, COX-2 has an important role in the effects of rebamipide on gastric mucosal protection.	rebamipide	52-62	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	6-11
11005231-6	2000	Rebamipide inhibited reorganization of alkaline phosphatase-containing granules along with upregulation of alkaline phosphatase activity and CD16, a marker of the granules.	rebamipide	0-10	Fc gamma receptor IIIa	Homo sapiens	141-145
10945834-2	2000	Furthermore, to define the action mechanisms, we determined the effect of rebamipide on the surface expression of endothelial cell adhesion molecules E-selectin, P-selectin, and intercellular adhesion molecule-1 (ICAM-1) on H/R-stimulated HUVECs.	rebamipide	74-84	selectin E	Homo sapiens	150-160
10945834-2	2000	Furthermore, to define the action mechanisms, we determined the effect of rebamipide on the surface expression of endothelial cell adhesion molecules E-selectin, P-selectin, and intercellular adhesion molecule-1 (ICAM-1) on H/R-stimulated HUVECs.	rebamipide	74-84	selectin P	Homo sapiens	162-172
10945834-2	2000	Furthermore, to define the action mechanisms, we determined the effect of rebamipide on the surface expression of endothelial cell adhesion molecules E-selectin, P-selectin, and intercellular adhesion molecule-1 (ICAM-1) on H/R-stimulated HUVECs.	rebamipide	74-84	intercellular adhesion molecule 1	Homo sapiens	178-211
10945834-2	2000	Furthermore, to define the action mechanisms, we determined the effect of rebamipide on the surface expression of endothelial cell adhesion molecules E-selectin, P-selectin, and intercellular adhesion molecule-1 (ICAM-1) on H/R-stimulated HUVECs.	rebamipide	74-84	intercellular adhesion molecule 1	Homo sapiens	213-219
10945834-6	2000	Rebamipide suppressed the surface expression of E-selectin and P-selectin with a subsequent inhibition of neutrophil adhesion to H/R-stimulated HUVECs.	rebamipide	0-10	selectin E	Homo sapiens	48-58
10945834-6	2000	Rebamipide suppressed the surface expression of E-selectin and P-selectin with a subsequent inhibition of neutrophil adhesion to H/R-stimulated HUVECs.	rebamipide	0-10	selectin P	Homo sapiens	63-73
10945834-8	2000	Taken together, this study demonstrates that rebamipide inhibits neutrophil adhesion to HUVECs by a mechanism involving inhibition of transcription-dependent surface expression of E-selectin and P-selectin in H/R-stimulated endothelial cells.	rebamipide	45-55	selectin E	Homo sapiens	180-190
10945834-8	2000	Taken together, this study demonstrates that rebamipide inhibits neutrophil adhesion to HUVECs by a mechanism involving inhibition of transcription-dependent surface expression of E-selectin and P-selectin in H/R-stimulated endothelial cells.	rebamipide	45-55	selectin P	Homo sapiens	195-205
16859283-6	2000	Pretreatment with rebamipide (100 and 300 mg kg(-1) day(-1), orally) significantly inhibited the expression of ICAM-1 with inhibition of mobilization of granulocyte/macrophage.	rebamipide	18-28	intercellular adhesion molecule 1	Rattus norvegicus	111-117
11007113-6	2000	Rebamipide significantly reduced concentrations of both interleukin-1alpha and GRO/CINC-1 (IL-8-like substance) and cell infiltrates in colonic wall, in parallel with decreased activity of myeloperoxidase.	rebamipide	0-10	interleukin 1 alpha	Rattus norvegicus	56-74
11007113-6	2000	Rebamipide significantly reduced concentrations of both interleukin-1alpha and GRO/CINC-1 (IL-8-like substance) and cell infiltrates in colonic wall, in parallel with decreased activity of myeloperoxidase.	rebamipide	0-10	C-X-C motif chemokine ligand 1	Rattus norvegicus	79-82
11007113-6	2000	Rebamipide significantly reduced concentrations of both interleukin-1alpha and GRO/CINC-1 (IL-8-like substance) and cell infiltrates in colonic wall, in parallel with decreased activity of myeloperoxidase.	rebamipide	0-10	C-X-C motif chemokine ligand 1	Rattus norvegicus	83-89
11007113-6	2000	Rebamipide significantly reduced concentrations of both interleukin-1alpha and GRO/CINC-1 (IL-8-like substance) and cell infiltrates in colonic wall, in parallel with decreased activity of myeloperoxidase.	rebamipide	0-10	myeloperoxidase	Rattus norvegicus	189-204
10882227-0	2000	Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa.	rebamipide	10-20	prostaglandin E receptor 4	Rattus norvegicus	38-41
10882227-6	2000	Therefore, we tested the effect of rebamipide on EP4 gene expression in the gastric mucosa.	rebamipide	35-45	prostaglandin E receptor 4	Rattus norvegicus	49-52
10882227-10	2000	The effect of rebamipide on EP4 gene expression and PGE2 production in RGM1 cells was also investigated in vitro.	rebamipide	14-24	prostaglandin E receptor 4	Rattus norvegicus	28-31
10882227-12	2000	Oral rebami-pide significantly increased EP4 gene expression in the gastric antrum but not in the corpus after WRS.	rebamipide	5-16	prostaglandin E receptor 4	Rattus norvegicus	41-44
10882227-14	2000	In vitro, rebamipide significantly augmented EP4 gene expression in RGM1 cells, and PGE2 significantly increased the cAMP production by RGM1 cells incubated with rebamipide.	rebamipide	10-20	prostaglandin E receptor 4	Rattus norvegicus	45-48
9753220-8	1998	These studies demonstrated unique properties of rebamipide and convincingly showed that it increases gastric mucus glycoprotein components, stimulates migration and proliferation of wounded epithelial cell monolayers, increases expression of epidermal growth factor and its receptor in normal and ulcerated gastric mucosa, and scavenges active oxygen radicals.	rebamipide	48-58	epidermal growth factor	Homo sapiens	242-265
9862763-3	1999	The increased production of IL-8 and expression of IL-8 mRNA were significantly inhibited by rebamipide (100-1000 microM) in a concentration-dependent manner.	rebamipide	93-103	C-X-C motif chemokine ligand 8	Homo sapiens	28-32
9862763-3	1999	The increased production of IL-8 and expression of IL-8 mRNA were significantly inhibited by rebamipide (100-1000 microM) in a concentration-dependent manner.	rebamipide	93-103	C-X-C motif chemokine ligand 8	Homo sapiens	51-55
9862763-5	1999	Rebamipide also suppressed the adherence of neutrophils to endothelial cells as well as the expression of CD11b on neutrophils induced by formyl-methionyl-leucyl-phenylalanine and CM.	rebamipide	0-10	integrin subunit alpha M	Homo sapiens	106-111
9862763-7	1999	It is concluded that rebamipide exerts its preventive effect against H. pylori-evoked gastric mucosal cell inflammation by inhibition of the neutrophil adherence to the endothelial cells as well as by suppressing the surface expression of CD11b on neutrophils and the production of proinflammatory cytokine such as IL-8 from gastric epithelial cells.	rebamipide	21-31	integrin subunit alpha M	Homo sapiens	239-244
9862763-7	1999	It is concluded that rebamipide exerts its preventive effect against H. pylori-evoked gastric mucosal cell inflammation by inhibition of the neutrophil adherence to the endothelial cells as well as by suppressing the surface expression of CD11b on neutrophils and the production of proinflammatory cytokine such as IL-8 from gastric epithelial cells.	rebamipide	21-31	C-X-C motif chemokine ligand 8	Homo sapiens	315-319
9753237-4	1998	In a cell-free system, rebamipide did not affect iNOS enzyme activity; however, rebamipide inhibited iNOS mRNA and protein expression induced by IFN-gamma.	rebamipide	80-90	nitric oxide synthase 2, inducible	Mus musculus	101-105
9753232-10	1998	Myeloperoxidase activity in the gastric mucosa tended to increase in the placebo group, but tended to decrease in the rebamipide group.	rebamipide	118-128	myeloperoxidase	Homo sapiens	0-15
9753237-4	1998	In a cell-free system, rebamipide did not affect iNOS enzyme activity; however, rebamipide inhibited iNOS mRNA and protein expression induced by IFN-gamma.	rebamipide	80-90	interferon gamma	Mus musculus	145-154
9753237-5	1998	Thus, we concluded that rebamipide inhibited IFN-gamma-induced NO production as a result of its inhibitory action on iNOS mRNA expression.	rebamipide	24-34	interferon gamma	Mus musculus	45-54
9753237-5	1998	Thus, we concluded that rebamipide inhibited IFN-gamma-induced NO production as a result of its inhibitory action on iNOS mRNA expression.	rebamipide	24-34	nitric oxide synthase 2, inducible	Mus musculus	117-121
9753237-1	1998	To investigate the effects of rebamipide, an antigastritis and anti-gastric ulcer drug, on inducible nitric oxide synthase (iNOS), murine macrophage RAW264.7 cells were treated with interferon-gamma (IFN-gamma) in the presence of rebamipide.	rebamipide	30-40	nitric oxide synthase 2, inducible	Mus musculus	124-128
9753237-2	1998	NO production was stimulated by IFN-gamma, and the level was attenuated by rebamipide in a dose-dependent manner.	rebamipide	75-85	interferon gamma	Mus musculus	32-41
9753243-3	1998	The increased activities of serum ALT, AST, and LDH, but not serum nitrite were significantly inhibited by rebamipide (100 mg/kg, orally for five days).	rebamipide	107-117	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	39-42
9753237-3	1998	Therefore, we investigated the possibility that either rebamipide directly inhibited iNOS enzyme activity or that it reduced iNOS mRNA expression.	rebamipide	55-65	nitric oxide synthase 2, inducible	Mus musculus	85-89
9753243-4	1998	Myeloperoxidase activity in the liver was significantly elevated in the rats with endotoxemia by 2.4-fold (P &lt; 0.05), which was also significantly inhibited by rebamipide.	rebamipide	163-173	myeloperoxidase	Rattus norvegicus	0-15
9190883-0	1997	Effects of rebamipide in a model of experimental diabetes and on the synthesis of transforming growth factor-beta and fibronectin, and lipid peroxidation induced by high glucose in cultured mesangial cells.	rebamipide	11-21	fibronectin 1	Rattus norvegicus	118-129
9753243-6	1998	The increased TNF-alpha level measured at 1 hr was significantly inhibited by pretreatment with rebamipide (100 mg/kg for five days).	rebamipide	96-106	tumor necrosis factor	Rattus norvegicus	14-23
9753243-7	1998	It is suggested that rebamipide exerts a strong protective effect on the LPS-induced liver damage through inhibition of activation of neutrophils and TNF-alpha production.	rebamipide	21-31	tumor necrosis factor	Rattus norvegicus	150-159
9190883-3	1997	Our study examines whether rebamipide could ameliorate the pathophysiology associated with experimental diabetes in vivo, such as microalbuminuria, and to reverse the increased production of transforming growth factor-beta1 and fibronectin in SV-40 transformed murine mesangial cells in culture that were stimulated with high glucose.	rebamipide	27-37	transforming growth factor, beta 1	Mus musculus	191-223
9190883-3	1997	Our study examines whether rebamipide could ameliorate the pathophysiology associated with experimental diabetes in vivo, such as microalbuminuria, and to reverse the increased production of transforming growth factor-beta1 and fibronectin in SV-40 transformed murine mesangial cells in culture that were stimulated with high glucose.	rebamipide	27-37	fibronectin 1	Mus musculus	228-239
9190883-7	1997	Rebamipide 2 mM was as effective as 20 mM of dimethylthiourea, a known hydroxyl radical scavenger, in inhibiting the increase in lipid peroxides, transforming growth factor-beta1, fibronectin mRNAs and proteins induced by incubation of cultured mesangial cells with high glucose.	rebamipide	0-10	transforming growth factor, beta 1	Rattus norvegicus	146-178
9190883-7	1997	Rebamipide 2 mM was as effective as 20 mM of dimethylthiourea, a known hydroxyl radical scavenger, in inhibiting the increase in lipid peroxides, transforming growth factor-beta1, fibronectin mRNAs and proteins induced by incubation of cultured mesangial cells with high glucose.	rebamipide	0-10	fibronectin 1	Rattus norvegicus	180-191
8654144-3	1996	Rebamipide, at concentrations of 10(-5) and 10(-6) M, reduced the adherence of neutrophils to endothelial cells as well as the CD18 expression on neutrophils induced by this bacterial extract.	rebamipide	0-10	integrin subunit beta 2	Homo sapiens	127-131
33232357-0	2020	Assessment of mucin-related gene alterations following treatment with rebamipide ophthalmic suspension in Sjogren"s syndrome-associated dry eyes.	rebamipide	70-80	LOC100508689	Homo sapiens	14-19
33232357-3	2020	In addition, we investigated alterations in mucin-related gene expression secondary to treatment with rebamipide ophthalmic suspension in patients with Sjogren"s syndrome-associated dry eyes (SS-DE).	rebamipide	102-112	LOC100508689	Homo sapiens	44-49
35184054-10	2022	Adding either exogenous mucin or the mucin secretagogue, rebamipide, partially alleviated the PSL-induced dysbiosis of the gut microbiota.	rebamipide	57-67	LOC100508689	Homo sapiens	37-42
8788414-7	1995	Rebamipide prevented the decrease of the NADPH-cytochrome P450 reductase activity but had little effect on the cytochrome P450 content.	rebamipide	0-10	cytochrome p450 oxidoreductase	Rattus norvegicus	41-72
7562569-4	1995	Pretreatment with rebamipide significantly reduced the activity of myeloperoxidase (an index of neutrophil infiltration) and preserved the activities of superoxide dismutase and nitric oxide synthase in the gastric mucosa with inhibition of malondialdehyde production.	rebamipide	18-28	myeloperoxidase	Rattus norvegicus	67-82
8774986-4	1995	In the lansoprazole-treated cases, the content and the histochemical immunoreactive area of bFGF significantly increased 4 weeks after the treatment, compared with the group treated with rebamipide and the control group.	rebamipide	187-197	fibroblast growth factor 2	Homo sapiens	92-96
8774986-5	1995	In the famotidine-treated group, the concentration of bFGF significantly increased, compared with the rebamipide-treated group, and not with control.	rebamipide	102-112	fibroblast growth factor 2	Homo sapiens	54-58
34742693-0	2021	Strengthened rebamipide ocular nanoformulation to effectively treat corneal alkali burns in mice through the HMGB1 signaling pathway.	rebamipide	13-23	high mobility group box 1	Mus musculus	109-114
35118894-8	2022	RESULTS: In vitro, rebamipide/NPs dose-dependently suppressed the mRNA levels of pro-inflammatory mediators, including interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, matrix metalloproteinase (MMP)-3, MMP-13, and cyclo-oxygenase-2.	rebamipide	19-29	interleukin 1 alpha	Rattus norvegicus	119-141
35118894-8	2022	RESULTS: In vitro, rebamipide/NPs dose-dependently suppressed the mRNA levels of pro-inflammatory mediators, including interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, matrix metalloproteinase (MMP)-3, MMP-13, and cyclo-oxygenase-2.	rebamipide	19-29	interleukin 6	Rattus norvegicus	143-147
35118894-8	2022	RESULTS: In vitro, rebamipide/NPs dose-dependently suppressed the mRNA levels of pro-inflammatory mediators, including interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, matrix metalloproteinase (MMP)-3, MMP-13, and cyclo-oxygenase-2.	rebamipide	19-29	tumor necrosis factor	Rattus norvegicus	149-176
35118894-8	2022	RESULTS: In vitro, rebamipide/NPs dose-dependently suppressed the mRNA levels of pro-inflammatory mediators, including interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, matrix metalloproteinase (MMP)-3, MMP-13, and cyclo-oxygenase-2.	rebamipide	19-29	matrix metallopeptidase 3	Rattus norvegicus	178-210
35118894-8	2022	RESULTS: In vitro, rebamipide/NPs dose-dependently suppressed the mRNA levels of pro-inflammatory mediators, including interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, matrix metalloproteinase (MMP)-3, MMP-13, and cyclo-oxygenase-2.	rebamipide	19-29	matrix metallopeptidase 13	Rattus norvegicus	212-218
35118894-8	2022	RESULTS: In vitro, rebamipide/NPs dose-dependently suppressed the mRNA levels of pro-inflammatory mediators, including interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, matrix metalloproteinase (MMP)-3, MMP-13, and cyclo-oxygenase-2.	rebamipide	19-29	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	224-241